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IX 
SUMMARY	  
Medulloblastoma comprises the most common malignant brain tumor in children and one 
of the leading causes of cancer-related mortality in this age group. Despite significant 
therapeutic achievements within the last three decades, medulloblastoma is still 
associated with a comparably poor overall survival rate of only 70%. Moreover, many 
patients suffer from severe adverse effects from adjuvant chemo- or radiotherapy. A 
better understanding of the underlying molecular pathomechanisms could reveal more 
targeted therapeutic approaches for molecular subgroups to enhance individual 
outcome. In the present study, comparative array-CGH and genome-wide expression 
profiling analyses (n=64) demonstrated that copy-number aberrations at the genomic 
locus of serum- and glucocorticoid regulated kinase (SGK1) at 6q23 were tightly 
correlated with mRNA abundance. Immunohistochemical examinations in an indepen-
dent patient cohort (n=260) and correlation with follow-up data revealed a significant 
association of SGK1 immunopositivity with poor overall survival as assessed by Kaplan-
Meier analysis (p = 0.0168). Based on this integrative genomics approach, SGK1 was 
suggested as a novel prognostic marker, and SGK1 immunohistochemistry may serve as 
a powerful diagnostic tool in medulloblastoma patients. SGK1 encodes a kinase with 
high sequence- and structural homology to the anti-apoptotic kinase AKT/PKB and, as 
the name implicates, it is transcriptionally up-regulated by serum and glucocorticoids. 
SGK1 was previously found to play a role in promoting cell survival and cell-cycle 
progression by phosphorylating diverse downstream targets such as FOXO3a, GSK-3β, 
p27, and NDRG1. Functional analyses in vitro conducted in this project demonstrated 
that loss of SGK1 function causes apoptosis induction and that stable overexpression of 
SGK1 promotes migration. Furthermore, a presumptive impairment in chemotherapy 
sensitivity, caused by ectopic SGK1 overexpression, has been observed in medullo-
blastoma cells. These findings provide in vitro evidence for a crucial role of SGK1 in 
medulloblastoma biology making it a prime candidate for targeted therapy in high-risk 
medulloblastoma patients. 
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X 
ZUSAMMENFASSUNG	  
Medulloblastome sind die häufigsten malignen Hirntumoren, die im Kindesalter auftreten 
und stehen an der Spitze der krebsassoziierten Todesursachen dieser Altersgruppe. 
Trotz bedeutender therapeutischer Errungenschaften während der letzten drei 
Jahrzehnte, sind Medulloblastome immernoch mit verhältnismäßig schlechten 
Gesamtüberlebensraten von nur 70% verbunden. Darüber hinaus kommt es bei vielen 
Patienten zu starken Nebenwirkungen von Radio- und Chemotherapie. Ein besseres 
Verständnis der zugrundeliegenden molekularen Pathomechanismen könnte spezi-
fischere zielgerichtete Therapieansätze für bestimmte Subgruppen aufzeigen, um 
einzelne Befunde zu verbessern. In der vorliegenden Studie haben vergleichende 
Analysen von genomischen Aberrationen mit korrespondierenden Expressionsprofilen 
(n=64) ergeben, dass der DNA-Kopienzugewinn im Genlocus von Serum- und Gluko-
kortikoid-regulierter Proteinkinase (SGK1) auf Chromosom 6q23 mit mRNA Abundanz 
korreliert ist.  Immunohistochemische Untersuchungen in einer unabhängigen Patienten-
kohorte (n=260) wurden mit klinischen Daten korreliert und ergaben eine signifikante 
Assoziation von SGK1 Immunfärbung mit schlechter Überlebensrate, die mit Hilfe der 
Kaplan-Meier Analyse bestimmt wurde (p = 0.0168). Basierend auf diesem integrativen 
Ansatz konnte SGK1 als neuer prognostischer Biomarker vorgeschlagen werden. Dabei 
könnte die SGK1 Immunfärbung als vielversprechendes diagnostisches Hilfsmittel bei 
Medulloblastompatienten dienen. SGK1 codiert für eine Kinase mit hoher Sequenz- und 
Strukturhomologie zur anti-apoptotischen Kinase AKT/PKB. Wie der Name bereits 
impliziert, wird sie auf transkriptioneller Ebene durch Serum und Glukokortikoide 
hochreguliert. SGK1 wurde sowohl eine Pro-Survival Rolle, als auch positive Be-
einflussung der Zellzyklus-Progression zugeschrieben. Diese Effekte werden durch 
Phosphorylierung verschiedener Zielmoleküle, wie zum Beispiel FOXO3a, GSK-3β, p27 
und NDRG1, vermittelt. Funktionelle in vitro Analysen in dieser Studie haben gezeigt, 
dass der Verlust von SGK1-Funktionalität Apoptose induziert und SGK1 Überexpression 
die Migration fördert. Des Weiteren wurde eine mutmaßliche Beeinträchtigung der 
Sensitivität gegenüber Chemotherapeutika festgestellt, die durch ektopische Über-
expression von SGK1 in Medulloblastom Zelllinien hervorgerufen wurde. Diese Erkennt-
nisse liefern in vitro Beweise dafür, dass SGK1 eine entscheidende Rolle in der Biologie 
des Medulloblastoms spielt. Deshalb ist es ein wichtiger Kandidat für zielgerichtete 
Therapie in Hochrisiko-Medulloblastompatienten. 
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1 
1 INTRODUCTION	  
1.1 CANCER	  
Multicellular organisms hold complex mechanisms allowing proper development, survival 
and maintenance of cellular homeostatis. There is a manifold interplay of diverse cells 
within the body, which needs to be tightly regulated because failures can have harmful 
consequences such as cancer. 
Malignant cells generally constitute a neoplastic burden, which can develop within almost 
every tissue in the body. To date, more than 200 different known human cancer entities 
have been described1. The majority of human tumors derives from epithelial tissues and 
is named carcinomas. Other solid tumors arising from the mesenchyme are referred to 
as sarcomas. Another group of non-epithelial cancers comprises tumors of the nervous 
system, which consist of ectodermally derived tissue. These entities are called according 
to their proposed cell of origin. Thus, medulloblastoma refers to the medulloblast, a 
progenitor cell that is proposed to build the medulla oblongata. Furthermore, 
malignancies can occur from the hematopoietic system such as leukemias and 
lymphomas2. 
 
1.1.1 The Hallmarks of Cancer 
Tumorigenesis is a multistep process with each step being an advancement for a normal 
cell on the way to turn into a malignant progeny. Thus, for the transformation into a 
malignant tumor cell, a microevolution has to be undergone, which is accompanied by 
the acquisition of several properties enabling unrestricted growth within the host body. 
Certain features allow tumor cells to evade control mechanisms. Solid tumors commonly 
exhibit the following characteristics, which have been summarized as ‘hallmarks of 
cancer’ by Hanahan and Weinberg in 20003 (Figure 1). 
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Figure 1 The Hallmarks of Cancer. The illustrated characteristics can be considered as the classical 
hallmark capabilities of cancer described by Hanahan and Weinberg in 2000. Adapted from Hanahan et al.4 
 
Independence of external growth signals 
At early oncogenic stages, a dividing cell clone becomes independent of mitogenic 
growth signals provided by its microenvironment through the acquisition of genetic or epi-
genetic alterations. The achievement of self-sufficient proliferation is a key step of tumor 
initiation and is often referred to as neoplastic transformation. This can be achieved by 
an autocrine production of growth factors by the cancer cells themselves. Alternative 
mechanisms are the overexpression or hyperresponsiveness of cell surface receptors or 
switching on downstream signaling pathways independent of prior growth factor binding 
to these receptors. For example, the RAS (rat sarcoma) signaling pathway mediates 
survival and proliferation. It is downstream of various receptor tyrosine kinases and RAS 
mutations have been found in many human cancers5. 
 
Insensitivity to anti-growth signals 
The growth advantage of certain sub-clones occurs through further (epi)genetic changes 
to generate new phenotypes. Another hallmark of cancer cells dealing with signals 
provided by the microenvironment consists of the circumvention of growth suppressors. 
In normal tissues, cellular quiescence is maintained by soluble anti-growth factors like 
TGFβ (transforming growth factor-β) in addition to other extracellular matrix components. 
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TGFβ mediates cell cycle arrest in G1-phase to block proliferation, furthermore it induces 
cell differentiation and apoptosis. Many tumor cells lack anti-growth inhibition by TGFβ 
caused by mutations, which leads to uncontrolled proliferation6. 
 
Evasion of cell death 
Beyond autonomous proliferation, tumor cells need to acquire additional capabilities to 
overcome homeostatic barriers e.g. to circumvent cell death - mainly apoptosis. 
Apoptosis is the process of programmed cell death and can be triggered by both intrinsic 
or extrinsic signals. Eventually, cell death procedes in defined steps like membrane 
blebbing, chromosome degradation and nucleus fragmentation. The accumulation of 
several abnormalities causes apoptotic crisis in healthy cells, but not in cancer cells - 
highlighting the evasion of apoptosis as one major hallmark of tumorigenesis7. In normal 
cells, p53 is a cellular gatekeeper by controling cell cycle progression and apoptosis8. 
Malignant cells often lack functional p53, thus apoptosis is prevented. Besides evading 
apoptosis, tumor cells need to avoid other processes such as senescence and 
autophagy. The latter one is a catabolic mechanism to reallocate nutrients in starving 
cells9. Senescence is a post-mitotic state, in which the cell has lost its proliferative 
capacity10. 
 
Unlimited replicative potential  
Further microevolutionary steps have to be fulfilled in order to build a tumor bulk. Normal 
differentiated cells can undergo only a defined number of divisions. This is due to the 
shortening of the telomeres in each DNA replication step. Upon reaching a critical length, 
replicative senescence is induced. In order to achieve the capability of limitless 
selfreplication, malignant tumor cells have to adapt in maintaining telomeres for acquiring 
immortality. To this end, the majority of tumor cells re-activates telomerase, a ribo-
nucleoprotein complex that synthesizes telomeric DNA. Another mechanism is the 
recombination-based process of alternative lengthening of telomeres (ALT)11. 
 
Induction of angiogenesis 
When a solid tumor has accumulated the previous characteristics and reached a certain 
dimension, the supply with oxygen and nutrients becomes insufficient. To overcome this 
deficiency, the tumor undergoes an angiogenic switch from the avascular to the vascular 
phase. For this, a neo-vascularization process penetrating the tumor mass is needed12. 
Angiogenesis is triggered and coordinated by a multitude of soluble factors like HIF 
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(hypoxia inducible factor), VEGF (vascular endothelial growth factor) or ANG1 
(angiopoetin-1), which are often deregulated in tumor cells13. 
 
Tissue invasion and metastasis 
Another important hallmark of tumor cells is their capability to invade and metastasize14. 
This ability is only achieved by a small sub-population within the tumor15. Physical 
boundaries have to be overcome to spread and colonize at distant organs. The first step 
in metastasis is becoming invasive, which is facilitated by the loss of cell-cell adhesion 
molecules. The epithelial to mesenchymal transition (EMT) process, in which epithelial 
cells switch to a mesenchymal progenitor phenotype, empowers malignant cells to 
detach and enter blood vessels. Furthermore, matrix metalloproteinases (MMPs) play a 
crucial role in metastasis. Their upregulation enables the cells to overcome the 
extracellular matrix boundary16. Accordingly, some of the disseminated cancer cells will 
find a new microenvironment, where they are able to settle down and grow. 
 
Recently, a complementing review to the publication of 2000 has been published by 
Hanahan and Weinberg. They extend the number of classical cancer hallmarks to 
include four additional characteristics that enable progression of a neoplasia4 (Figure 2). 
 
Figure 2 Emerging Hallmarks and Enabling Characteristics. Recent research has highlighted the 
importance of complementary capabilities of cancer additionally to the classical hallmarks. Adapted from 
Hanahan et al.4  
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Immune escape 
Interaction of premalignant clones with the microenvironment, especially immune cells 
interfere with tumorigenesis. According to the theory of immune surveillance, the immune 
system counteracts uncontrolled cell growth by secreting ligands, such as members of 
the TNF (tumor necrosis factor) family17. Every cell is monitored by an alert system of the 
immune system to erase transformed cells. Consequently, malignant tumor cells need 
the capability to evade the immune response. Hence, this is another hallmark of cancer.  
 
Deregulation of energy metabolism 
The ability of cancer cells to switch their energy metabolism from normal aerobic 
mitochondrial respiration to glycolysis has been found in various tumors. In normal cells, 
this process only occur under anaerobic conditions, whereas it is a widespread 
phenomenon in fast-growing cancers even under aerobic conditions. This effect was first 
described by Otto Warburg in 192418. In the last years, deeper scientific insights 
reinforced the concept of metabolic reorientation in tumor cells. Although less ATP 
molecules are produced by glycolysis, there is a beneficial effect in generating diverse 
biomolecules like amino acids and nucleotides that are necessary for cell proliferation19. 
In addition, tumor cells counteract the lower ATP production in upregulating glucose 
transporters, for example GLUT1 (glucose transporter 1), which increases the glucose 
uptake20,21. 
 
Genome instability 
Another hallmark that is often found in cancer cells is genomic instability. The defects in 
genome maintenance and repair accumulating during cancer development provide 
advantages for the tumor and can support its progression. One reason for genetic 
instability is the loss of telomeric DNA22. A second explanation is the increased mutation 
rate in malignant cells and furthermore the lack of a proper cell control system, which 
normally eliminates defective cells23,24. 
 
Tumor-promoting inflammation 
The immune system also could play a supportive role for the tumor, basically in 
mediating chronic inflammation. Thereby, it contributes to various capabilities of malig-
nant cells such as supplying growth factors, survival factors, angiogenic factors, 
extracellular matrix modifying enzymes25. This leads in turn to the activation of the above 
mentioned hallmarks of cancer.  
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Notably, not all of the conditions described above have to be fulfilled for the development 
of a neoplasia. In general, a tumor, which grows within the natural boundaries of its 
tissue and does not infiltrate into the surrounding, is regarded as benign. Conversely, an 
invasive tumor phenotype, which is not locally restricted, is referred to as malignant. 
Different grades of malignancies occur within one type of cancer ranging from benign 
lesions to highly malignant and infiltrating tumors with the ability to metastasize. The 
most devastating stage is when a tumor starts to metastasize. This means that cells 
disseminate to form cancer colonies at distant sites of the body2. The model that the 
acquisition of fatal alterations occurs in a multistep process was initially demonstrated for 
colorectal cancer. Benign adenomas can transform to malignant carcinomas by 
accumulating several mutations over several years26,27. The probability to accumulate 
various alterations increases with the age of an organism and its exposure to carcino-
genic factors. Childhood malignancies exhibit a very early onset of disease, which is 
therefore an exeptional case. During the development from a healthy towards a 
malignant cell two classes of genes - tumor suppressor genes and oncogenes - play a 
critical role in gaining the previously described hallmarks. It is important to distinguish the 
'driver' mutations that push cells towards cancer from the 'passenger' mutations that are 
a by-product of cancer cell development28. 
 
1.1.2 Cellular Oncogenes 
Under physiological conditions homeostasis is maintained by balancing cell growth and 
cell death. A premalignant cell has to overcome a series of barriers to reach sustained 
and unrestricted cell growth, which gives rise to tumorigenesis. In this process, onco-
genes play a crucial role. Per definition oncogenes are cellular genes capable of 
accelerating proliferation in a dominant way on a cellular level upon activation. Their 
normal counterparts are referred to as proto-oncogenes. Major oncogenic mechanisms 
lead to a gain-of-function. This can be achieved by activating genetic mutations, 
translocations or amplifications resulting in overexpression. Proto-oncogenes are 
typically implicated in signal transduction promoting cell growth, cell proliferation, survival 
or induction of developmental processes and encode for proteins of different classes: 
growth factors, growth factor receptors, signal transducers, transcription factors, 
chromatin remodelers, and apoptosis regulators29. The first oncogene was discovered in 
1970 in a chicken retrovirus, the Rous Sarcoma Virus (RSV), and termed as v-src (avian 
sarcoma viral oncogene) due to its capability of transforming neoplastic disease in 
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chicken when overexpressed30,31. Later studies revealed that in untransformed host cells, 
a related gene (c-SRC) is present, which originally has been acquired by the virus32,33. 
The sarcoma viral oncogene homolog RAS is a downstream key mediator of extrinsic 
growth stimuli. Proteins of the RAS-family conduct mitogenic signals from growth factor 
receptors and other transmembrane proteins like integrins towards the cytoplasmic 
cascade of mitogen-activated protein kinases (MAPK)27. The activation of RAS due to 
aciquisitation of mutations has been described in various cancer types34,35. 
From a therapeutic point of view, the gain-of-function character of oncogenes offers 
promising implications in approaching inhibition of their function. Therefore, molecules 
have been developed to specifically target these proteins allowing rational treatment in 
contrast to conventional therapies, which are generally aimed at all dividing cells in the 
patient. This is achieved for example by imatinib/glivec, an ABL kinase inhibitor in CML, 
gefitinib/iressa targeting the EGF receptor in non small cell lung cancer (NSCLC) or 
Lapatinib/Tyverb used in breast cancer inhibiting ERBB2. These drugs are already in 
clinical use but require oncogene addiction of the tumor to this function36. 
 
1.1.3 Tumor Suppressor Genes 
In contrast to the growth promoting oncogenes, tumor suppressor genes protect a cell 
from one step on the path to cancer by exhibiting a suppressive function on cellular 
growth or inducing apoptosis. Therefore, under normal physiological conditions, these 
genes counteract the growth inducing effects of (proto-) oncogenes2. In tumorigenic pro-
cesses, mutations in tumor suppressor genes cause a loss-of-function and the cell can 
progress to cancer, usually in combination with other genetic changes. Mutant tumor 
suppressor alleles are usually recessive, whereas mutant oncogene alleles are typically 
dominant. Consequently, if only one allele for the tumor suppressor gene is damaged, 
the second one can still give rise to the correct protein. Thus, generally, both alleles of a 
tumor suppressor gene are inactivated or lost during oncogenesis, which is implied in the 
two-hit hypothesis introduced 1971 by Alfred Knudson. This discovery was initially found 
in cases of retinoblastoma caused by biallelic inactivation in the RB gene. Whereas the 
mutation of one allele is inherited via germ line, the second hit is acquired by 
spontaneous mutation of the remaining allele37. Nowadays, it is known that RB is a 
central player in many cancer-relevant pathways such as cell cycle regulation and 
apoptosis. Disrupted pRb/E2F interaction abrogates cell cycle control38,39. Furthermore, 
RB functions as an adaptor protein for chromatin remodeling enzymes. The importance 
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of RB is reflected by its frequent loss-of-function in many other human cancers besides 
in retinoblastoma40. Another example is given by the protein PTEN, which is encoded by 
the tumor suppresssor gene phosphatase and tensin homolog (PTEN). It acts by 
opposing the action of PI3K, which is essential for anti-apoptotic and pro-tumorigenic 
AKT activation41. However, there are also exceptions to the two-hit rule for tumor 
suppressors. A prominent example for this is protein 53 (p53). The TP53 gene product 
p53 is a short-lived transcription factor, which induces cell cycle arrest, senescence, 
DNA repair or apoptosis in response to cellular stresses like irradiation, hypoxia or DNA 
damage. Mutation of only one TP53 allele may lead to loss-of-function in a dominant 
negative manner because the protein exerts regulation as a homotetramer and this 
function is already lost by incorporation of already one mutant monomer42,43. If the p53 
pathway becomes activated in order to control DNA integrity and cell cycle progression, 
the protein is stabilized by uncoupling from its negative regulators MDM2 or MDM4, 
which leads to the accumulation of p53. Finally, homotetramers are formed to act as 
transcription factor inducing target gene expression. Loss of functional p53 is found in 
more than 50% of all human cancers illustrating that cellular growth control is an 
important aspect in cancer prevention44,45. Further exceptions to Knudson’s two-hit 
concept are given by the phenomenon of exhibiting haploinsufficiency such as e.g. 
PTCH in medulloblastoma and in the p27Kip1 mouse models. Here, already loss of only 
one allele of the tumor suppressor leads to predisposition for tumors46,47. Hence, the 
assumption that null mutations in tumor suppressor genes are recessive excludes those 
genes that exhibit haploinsufficiency. 
In the vast majority of sporadic cancers, somatic mutations or deletions are found, which 
occured spontaneously. In contrast, hereditary cancers are caused by germline 
mutations. Many hereditary cancer syndromes that are characterized by an increased 
risk of developing cancer have been described: Familial adenomatous polyposis (APC 
mutation), Li-Fraumeni-Syndrome (TP53 mutation), and Retinoblastoma (RB mutation)48. 
 
Targeting this group of genes therapeutically is much more demanding compared to the 
pharmacological inhibition of oncogenes, because the function of the gene (product) has 
to be restored. This could be accomplished by introducing tumor suppressor genes via 
gene therapy. Another indirect approach is the artificial induction of apoptosis by 
administration of agents targeting complementary processes as exemplified by the use 
of poly (ADP-ribose) polymerase (PARP) inhibitors such as olaparib and iniparib in 
BRCA-mutated breast cancers or PTEN-defective tumors (e.g. prostate cancer)49. 
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1.2 MEDULLOBLASTOMA	  
Medulloblastoma is the most common malignant brain tumor in children. The small blue 
cell malignancy constitutes a major cause of mortality in pediatric oncology. While rapidly 
fatal if untreated, current treatment regimens including surgery, state-of-the-art radiation 
and chemotherapy, result in overall survival rates exceeding 70%50. About 60% of 
reported cases in the United States (U.S.) occur in patients in the first 14 years of life. 
Peak age of incidence is 3-5 years and boys are almost twice as likely to develop 
medulloblastoma as girls. Medulloblastoma in adults is rare, comprising less than 1% of 
CNS malignancies51. 
According to the WHO (World Health Organization) classification of tumors of the central 
nervous system (CNS), medulloblastoma is a grade IV tumor of embryonal origin arising 
in the cerebellum. It is an invasive and rapidly growing tumor with the tendency to 
dissiminate through the cerebrospinal fluid (CSF) and metastasizes to other parts of the 
brain and the spine though this varies between different subtypes. Medulloblastoma 
growth penetrates the brainstem and the 4th ventricle because of its localization in the 
posterior fossa52. This brain area controls posture and complex motor functions such as 
balance and speech. For infants and older children with medulloblastoma, symptoms like 
lethargy, vomiting and headaches are very likely to occur, as well as problems in 
walking, speech, writing and double vision due to the tumor. Tumors located in the 
cerebellum, such as medulloblastoma are also referred to as infratentorial tumors, 
meaning that they are located below the tentorium. This thick membrane separates the 
two cerebral hemispheres of the brain from the cerebellum (Figure 3). 
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Figure 3 Diagram showing where the tentorium is located in the brain. Modified from CancerHelp UK1. 
 
1.2.1 Histopathology of Medulloblastoma 
Varying histopathological subtypes seen on biopsies are currently categorized into five 
main variants of medulloblastoma according to the WHO classification scheme: classic 
medulloblastoma, desmoplastic medulloblastoma, medulloblastoma with extensive 
nodularity (MBEN), large cell medulloblastoma, and anaplastic medulloblastoma. 
Morphologically, classic medulloblastoma is composed of densely packed cells with 
round-to-oval or carrot-shaped hyperchromatic nuclei marginally surrounded by 
cytoplasm. Neuroblastic (Homer Wright) rosettes consisting of tumor cell nuclei arranged 
in a parallel or circular manner are observed in less than 40% of these cases and are 
often associated with high mitotic activity. Classic medulloblastomas develop in the 
cerebellar vermis and affect mostly older children. The desmoplastic variant is 
characterized by focal appearance of nodules with few differentiated neurocytic cells 
including reticulin-free zones (pale islands) surrounded by internodular regions of 
densely packed, less differentiated and highly proliferative cells. The nodules represent 
areas of neuronal maturation exhibiting a reduced nuclear-to-cytoplasmic ratio. The 
maturated cells show negligible mitotic activity and increased apoptosis. In contrast to 
classic medulloblastomas, the desmoplastic subtype is mainly found in the hemispheres 
of the cerebellum and accounts for more than 50% of all cases occurring in infants < 3 
years of age. This histologic variation also encompasses the MBEN subtype that was 
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previously designated ‘cerebellar neuroblastoma. It is marked by a lobular archticture 
with numerous and particularly enlarged reticulin-free zones and rich neuropil-like tissue. 
These nodules of neurocytic cells exhibit a streaming pattern in the fibrillary background, 
whereas in some areas the internodular component is markedly reduced. The term large 
cell medulloblastoma describes already the distinctive phenotype of monomorphic cells 
with large, round, and vesicular nuclei harboring prominent nucleoli. Due to a lack of 
cohesiveness, the cells of this variant show the highest mitotic and apoptotic rates 
among all medulloblastoma histotypes. There is a considerable cytologic overlap in 
features like pleomorphism and high cell turnover to the anaplastic subtype, for which a 
combined large cell/ anaplastic (LCA) medulloblastoma category has been proposed. 
The anaplastic variant also includes tumors with atypical cell forms. However, both 
variations are characterized by an aggressive behavior resulting in poor clinical outcome. 
The heterogeneity within this group is reflected in the histopathological picture as well as 
in the variability in the age of onset ranging from below 3 to 16 years of age50. Medullo-
myoblastoma (with myogenic differentiation) and melanocytic medulloblastoma (with 
melanocytic differentiation) complete the histologic spectrum, whereas they are no longer 
considered separate variants because their phenotypic tumor cells can occur in different 
other medulloblastoma subtypes and they share genetic profiles. To sum up, there are 
currently three (since two are combined) main medulloblastoma subtypes distinguished 
in neuropathology accompanied by well-defined differences in age distribution (Table 1), 
to which particular ICD-O codes (International Classification of Disease for Oncology)50 
were assigned53,54. 
 
 
Table 1 Histological variants of medulloblastoma and frequencies in different age groups. 
Medulloblastoma 
subtype 
ICD-O 
code 
All childhood 
medulloblastoma 
Children           
< 3 years 
Children 3-16 
years 
Median    
age at 
presentation 
Classic 9470/3 73% 26% 78% 8.1 years 
Desmoplastic/ 
MBEN 
9471/3 10% 57% 5% 2.7 years 
Large cell/ 
anaplastic 
9474/3 17% 17% 17% 6.8 years 
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1.2.2 Cellular Origin of Subtypes 
In the cancer stem cell (CSC) hypothesis context, it is currently thought that embryonal 
tumors such as medulloblastoma arise from transformed neural stem cells and/or 
granule neuron progenitors of cerebellar origin, which were prevented from differentiating 
into their normal physiological cell stage55. In many ways, medulloblastoma and neural 
stem cells share cellular and molecular similarities. Recent studies show evidence that 
genetic anomalies in developmental pathways required for the normal maturation of the 
cerebellar cortex, in particular developmental pathways for granule cell progenitor (GCP) 
neurogenesis, give rise to medulloblastoma formation. Analysis of murine transgenic 
lines have confirmed that lineage-restricted progenitors or stem cells of the external 
granular layer (EGL) can be transformed into a medulloblastoma, via activated sonic 
hedgehog (SHH) signaling pathway56. Tumors associated with desmoplastic histology 
originate from GCPs in the EGL that often carry mutations in SHH signaling pathway 
effectors (PTCH1, Smo). Furthermore, stem and/or progenitor cell populations outside 
the EGL are also believed to serve as cells of origin for a subset of medulloblastomas. 
Indeed, many non-nodular tumors express markers suggesting that they are derived 
from the ventricular zone (VZ) germinal layer, showing evidence of Wnt pathway 
activation driven by activating mutations in APC/ß-catenin, which are present in a 
fraction of classic medulloblastomas. Focal high-level amplifications of MYC(N) are 
frequently associated with LCA medulloblastoma subtype57-60. 
The ‘medulloblast’ for other subsets of medulloblastoma has yet to be elucidated. An 
overview of the histopathological medulloblastoma subtypes and their proposed cellular 
origin is shown in Figure 4. Early postnatal GCPs are a heterogenous population 
representing a subset of progenitors potentially with different patterns of connectivity and 
different susceptibility to tumorigenesis. The precise identification of subpopulations of 
normal GCPs responsible for each subset of medulloblastoma requires genomic 
clustering studies and massive sequencing analysis of single cells to define genetic 
differences and alterations61. 
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Figure 4 Histopathological subtypes of medulloblastoma and their proposed cellular origin. Stem 
and/or progenitor cells derived from the ventricular zone (VZ) are thought to give rise mainly to the classic 
medulloblastoma variant one fraction of these being dependent on APC/ß-catenin mutations activating 
aberrant WNT signaling. Copy-number changes of chromosome17q/17p and MYC/MYCN amplifications are 
observed in the classic subtype but may also give rise to LCA medulloblastoma. In contrast, progenitor cells 
in the external granular layer (EGL) are proposed to give rise to mainly nodular/desmoplastic medullo-
blastoma. They achieve malignancy via constitutive sonic hedgehog (SHH) activation. Further acquisition of 
MYCN amplifications could transform them to LCA tumors. Other cerebellar stem cells or progenitors are 
discussed to be origin of other medulloblastoma variants (modified from Fan et al. 62 and Louis et al.50  
 
Etiology and Deregulated Pathways in Medulloblastoma Subgroups 
Although the cause of medulloblastoma is still unclear, several research groups across 
the globe are making significant progress in understanding its biology. Various genomic 
aberrations have been identified to play a role in the development of medulloblastoma. 
For example, the loss of the distal part of chromosome 17, distal to the TP53 gene, 
possibly accounts for oncogenic transformation of undifferentiated cerebellar cells. 
Moreover, there are a few rare hereditary tumor syndromes associated with increased 
risk for developing these tumors. Medulloblastomas were seen in patients with Gorlin 
syndrome (OMIM #109400), Turcot syndrome (OMIM #276300), as well as Li-Fraumeni 
syndrome (OMIM #151623)61,63. Table 2 shows an overview of dysfunctional signaling 
pathways in association with medulloblastoma. 
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Table 2 Signaling pathways in cerebellar development and associated dysfunction in medullo-
blastoma subtypes. Modified from Hatten et al.61 
Signaling 
pathway 
Normal pathway 
function 
Disease Mutations and/or 
abnormalities 
Medullo-
blastoma 
subtype 
Mechanism of 
oncogenesis 
Wnt Cell proliferation Turcot 
Syndrome 
and MB 
ß-Catenin, APC     
and Monosomy 6 
WNT Upregulated 
transcription of 
proliferative genes 
SHH/Ptch Cell proliferation Gorlin 
Syndrome 
Germline loss of 
function in Ptch1   
and Sufu 
SHH Increased cell division 
and loss of cell cycle 
exit 
Notch 2 Cell proliferation Medullo-        
blastoma 
Notch2, Jag1      
and Hes1 
overexpression 
Unknown Loss of cell cycle 
arrest 
BMP 2, 4 Cell cycle arrest 
and neuronal 
differentiation 
Gorlin 
Syndrome 
BMP pathway 
genes 
downregulated 
SHH Downregulation of 
expression, loss of 
cell cycle arrest and 
differentiation 
P53 cell cycle control 
and DNA damage 
response 
Li-
Fraumeni 
syndrome 
Loss-of-function 
mutation in TP53 
SHH Failure of cell cycle 
arrest, senescence or 
apoptosis 
 
The first indication that inherited mutations in developmental genes contribute to 
medulloblastoma was the finding that germ line mutations in the PTCH1 gene pre-
dispose Gorlin syndrome patients to develop medulloblastoma. Gorlin syndrome is an 
inherited condition associated with nevoid basal cell carcinoma in combination with other 
symptoms and/or malignancies such as medulloblastoma64,65. Focused attention on 
abnormalities in SHH signaling in hereditary medulloblastoma discovered inactivating 
germ line mutations in genes coding for the SHH receptor PTCH1, in the G protein-
coupled Smoothened receptor (SMO), or occasionally in the SHH inhibitor SUFU66-69. 
These mutations result in aberrant activation of the SHH pathway. This pathway is 
crucial for normal formation of the cerebellum, because it governs the proliferation of the 
most abundant neuronal population in the brain: the granule neuron precursor (GNP) 
cells. GNPs have been suggested to be the origin of medulloblastoma, arising as an 
abnormality of the normal development process, due to an aberrant proliferative stimulus 
created by constituviely active SHH signaling. If a GNP cell remains in the EGL and fails 
to exit the cell cycle, eventually this event may result in tumorigenesis70. In its normal 
physiological role, the trans-membrane protein PTCH1 functions as a receptor for SHH. 
In absence of the SHH ligand, PTCH1 maintains the SHH pathway in the off state by 
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acting on smoothened (SMO). Upon SHH binding to the receptor, this repression is 
released and a signal is transduced through SMO to the nucleus thereby increasing the 
expression of target genes such as GLI1 and PTCH1 itself (Figure 5)71. 
 
A similar paradigm is given by two other inherited syndromes, so called Li-Fraumeni and 
Turcot, containing genetic changes in the TP53 and APC  genes, respectively. Li-
Fraumeni syndrome is a hereditary disorder with autosomal dominantly inherited 
mutations of the gene coding for the p53 tumor suppressor, which predisposes affected 
patients to develop all kind of tumors72,73. Mutant p53 can be conductive for tumor 
formation due to aberrant cell cycle control and failure of cell cycle arrest, senescence or 
apoptosis induction74,75. Patients with Turcot syndrome tend to develop multiple colon 
polyps and malignant brain tumors. Turcot syndrome, also known as “mismatch repair 
cancer syndrome“ (MMRCS), is characterized by germline mutations of APC or biallelic 
mutations in DNA mismatch repair genes76,77. Investigation of this inherited syndrome 
leading to Wnt pathway activation contributed to uncover mutations of CTNNB1, APC, 
and AXIN1/2 in approximately 15% of sporadic medulloblastomas.  
The wild-type APC allele has been reported to be lost in a subset of medulloblastoma 
patients with underlying Turcot syndrome, suggesting that APC acts as a tumor 
suppressor in the cerebellum. Loss-of-function-mutations in the APC gene result in 
activation of the Wnt signaling pathway, which plays a major role in the regulation of cell 
proliferation and differentiation during CNS development as well as in tumorigenesis. ß-
catenin is a central effector of the Wnt pathway. The cytoplasmatic amount is controlled 
by AXIN1 and its homologue AXIN2 (Conductin), which function as Wnt antagonists and 
interact with APC and glycogen synthase kinase-3ß (GSK-3ß) to form a multiprotein 
complex. This so-called destruction complex promotes NH2-terminal phosphorylation of 
ß-catenin by GSK-3ß, marking it for degradation by the proteasome system (Figure 5). 
Besides genetic changes in the APC gene, which are found particularly frequent in colon 
cancers, oncogenic missense mutations in the N-terminal part of the ß-catenin gene 
have been shown in several cancers. This mutant form is resistant to ubiquitination and 
proteasomal degradation78,79, which leads to increased complex formation of nuclear ß-
catenin with the T-cell factor (TCF) resulting in elevated expression of Wnt target factors 
like Cyclin D1 and cMYC80,81.  
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Figure 5 SHH and Wnt signaling pathways. Inactive SHH pathway status: Ptch receptors inhibit 
Smoothened receptors (Smo, red) to prevent the access of Smo to the primary cilium. Smo receptors could 
be incororated by endosomes (blue). Gli2 and Gli3 are downstream effectors of the SHH pathway, SuFu 
binds them. Gli2 is also targeted for degradation via the proteasomal pathway which occurs in the cytoplasm 
and primary cilium. Active SHH pathway status: Ptch stops to repress Smo (green), which moves into the 
primary cilium. There, Kif7 aids activation of Gli proteins SuFu releases Gli2 and Gli3, and Gli2 translocates 
to the nucleus where it functions as a transcriptional activator. Gli3 exhibit repressor actions. Inactive Wnt 
pathway status: β-catenin, a central effector of Wnt signaling, is bound and phosphorylated in a multi-
protein complex consisting of Apc, Axin, CK1, and Gsk3ß. This so-called destruction complex processes ß-
catenin for degradation through the proteasomal pathway. Inactive Frizzled receptors are shown in red. 
Active Wnt pathway status: Wnt binds to Frizzled receptors to activate them (green). The complex is 
disrupted and allows β-catenin to accumulate and translocate to the nucleus. There it acts as a 
transcriptional activator. SFRP can bind Wnt to prevent the ligand binding to the receptor. Adapted from 
Ellison et al.53 
 
1.2.3 Molecular Subgroups of Medulloblastoma 
Current clinical classification schemes for medulloblastoma include histological sub-
grouping according to the WHO classification and clinical markers such as patient age at 
diagnosis, level of surgical resection, and mestatsic stage at diagnosis. Beyond these 
clinical characteristics, various research groups have begun to sub-classify 
medulloblastoma on the basis of genomewide transcriptional and genetic profiling 
studies to get a deeper insight into the underlying biological pathomechanisms82. This 
approach revealed distinct molecular subtypes differing in somatic genetic aberrations, 
transcriptional profiles, demographics, clinical outcome, and histology. A consensus 
conference in Boston, Massachusetts has taken place in fall 2010 to find an agreement 
about variations in composition and number of subgroups between different research 
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studies. The reached consensus nomenclature defines that four main molecular sub-
groups of medulloblastoma exist, which are called Wnt, SHH, Group 3, and Group 4 
(Figure 6)83,84. Beside the two subgroups Wnt and SHH, which are named according to 
the signaling pathways thought to play a driving role in their pathobiology, the other two 
remaining subtypes are termed Group 3 and Group 4 and often referred to  as non-
Wnt/non-SHH tumors. These are not obviously characterized by aberrant activation of 
specific signaling pathways, although there is an association with up-regulation of certain 
gene classes, such as photoreceptor genes and neuronal genes85,86. The four molecular 
subgroups are clearly distinct in terms of demographics, histology, cytogenetic 
aberrations, transcriptome, metastatic stage and clinical outcome. In the following 
section, the distinctive characteristics are described in more detail for each core 
subgroup. It is considered to adopt this molecular subgrouping system for more precise 
identification and outcome prediction of medulloblastoma patients in the clinic. 
Furthermore it is conductive to identify target cohorts for therapeutic stratification and 
treatment with certain drugs (e.g. SHH inhibitors).  
 
 
Figure 6 Overview of the various medulloblastoma subgroups including characteristic attributes. 
Adapted from Taylor et al.83 
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In contrast to tumors belonging to the SHH and Wnt subtypes, which are clearly 
separated from each other on principal components analysis after unsupervised 
hierarchical clustering of microarray gene expression data, the non-SHH/Wnt subgroups 
are not as clearly set aside from each other84, but are still different in a way that 
separation is justified. 
 
Wnt subgroup 
Patients harboring WNT-driven medulloblastoma exceed survival rates of about 90%83. 
Overall, medulloblastoma is more common in boys than in girls, but the gender ratio for 
WNT tumors is 1:1. WNT medulloblastomas are predominantly found in older children 
and teenagers (aged 4–15 years), and are rarely present in infants. Up to 25% of adult 
medulloblastomas can be categorized into the WNT subgroup87,88. Missense mutations in 
APC and AXIN1 have been identified in sporadic medulloblastoma resulting in 
overactivity of the canonical Wnt signalling pathway53,89. Additionally, up to 18% of 
medulloblastomas have been shown to exhibit somatic mutations of CTNNB1 encoding 
ß-catenin, which accounts for its nuclear accumulation leading to aberrant activation of 
the Wnt signaling pathway as first described by Ellison and colleagues. This genetic 
event is now commonly accepted as a hallmark for standard- (or low-) risk 
medulloblastoma90,91. The etiological role of canonical Wnt signaling in formation of 
medulloblastoma defines the nomenclature of these tumors as the “Wnt subgroup”. 
Nearly all tumors belonging to this subtype represent classic histology, regularly show 
nuclear ß-catenin accumulation and very often come along with monosomy 6 (deletion of 
one copy of chromosome 6). Indeed, there are also occasionally tumors showing a 
transcriptional Wnt signature without having an aberration in copy-number status of 
chromosome 684. Monosomy 6 is found in most cases of pediatric WNT 
medulloblastoma, whereas in adult WNT tumors monosomy 6 is evident in only half of 
cases, and has been also found in adult cases of SHH and Group 4 medulloblastomas. 
As such, monosomy 6 is a specific marker only for pediatric - and not for adult - WNT 
medulloblastoma. Metastatic dissemination at presentation is rare in cases of WNT 
medulloblastoma, and preliminary data suggest that metastatic dissemination may not 
have a negative prognostic value in this setting87. Despite the known hyperactivity of Wnt 
signalling in a number of common adult malignancies, e.g. in colon cancer, none of the 
current therapies that target this pathway have shown to be beneficial in patients with 
medulloblastoma. Although mutations in the tumor protein 53 (TP53) gene are commonly 
found in WNT medulloblastoma, agents that target mutant TP53 are not regularly used 
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for medulloblastoma therapy. Up to now, no other therapy targets for WNT 
medulloblastomas are known87. Gibson et al. recently published a medulloblastoma 
mouse model of the Wnt subtype suggesting that these tumors arise from the lower 
rhombic lip (LRL) from cells of the embryonic dorsal brainstem92. This model serves as 
preclinical tool for the assessment of novel therapeutics, as due to the good prognosis of 
Wnt medulloblastoma, many patients harboring this subtype presumably are overtreated 
by current therapy schemes. Active discussions about clinical trials of de-escalating 
therapies for WNT activated medulloblatoma patients are ongoing among experts83. 
 
Sonic hedgehog subgroup 
Similar to the WNT subgroup, the gender ratio in SHH medulloblastomas is 1:1. SHH 
medulloblastomas comprise the majority of tumors observed in infants and adults, but 
are less common in the intervening age groups87. As described in the preceding chapter, 
some individuals with Gorlin syndrome have a high risk of developing medulloblastoma. 
This hereditary syndrome is characterized by germline mutations in the PTCH1 tumor 
suppressor gene. Interestingly, the SHH medulloblastoma subgroup is characterized by 
deletion of chromosome 9q whereon the PTCH1 gene is located at 9q2284. Goodrich et 
al. developed a mouse model based on Ptch1 mutation resulting in murine medullo-
blastoma93. Other reports describe medulloblastomas being associated with somatic 
mutations in genes encoding for SHH pathway members, including SMO, PTCH2, 
SUFU, and GLI269,87. More than 30% of sporadic medulloblastoma show an over-
expression of GLI1, demonstrating that the SHH pathway has a major impact in 
tumorigenesis94. Furthermore, Rausch et al. recently reported on a striking connection 
between germline TP53 mutation (Li-Fraumeni syndrome) and SHH-medulloblastoma. 
Based on whole-genome sequencing they uncovered massive, complex chromosome 
rearrangements. This study revealed a striking link between TP53 mutation and 
chromotripsis in SHH medulloblastoma. On top of that, they speculated that this 
phenomenon is a key driver in the tumorigenesis of tumors63. However, the assignment 
of a tumor to the subgroup by histology is not an easy task. Histologically, the desmo-
plastic nodular subtype is restricted to the SHH medulloblastomas, although less than 
50% of SHH tumors exhibit this histopathology. Also MBEN is likely to be found in SHH 
medulloblastomas and the remaining proportion show classic histology. LCA histology 
has also been reported in the SHH subgroup. SHH is the only subgroup that includes 
tumors of all four major histological variants87. Metastases at the time of presentation are 
uncommon. Whereas metastases at presentation are a negative prognostic factor for 
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adults with SHH medulloblastoma, there is no evidence that metastases may have a 
negative prognostic value in infants with these tumors95. 
The most attractive therapeutic target in this medulloblastoma subgroup is given by the 
SHH pathway itself. There are several small molecule inhibitors of the SHH pathway, e.g. 
inhibitors of co-receptor smoothened (SMO), available for clinical trials. Administration of 
one such inhibitor showed beneficial effects in the beginning96. Unfortunately drug 
induced resistance to SMO inhibitor treatment occured in both mice and humans. 
Targeting of additional driver events in combination with SHH inhibition seems to be 
crucial to avoid drug resistance, as malignant clones that develop resistance to the anti 
SHH therapy are unlikely to be simultaneously also resistant to other targets. SMO 
inhibitors are on the way to phase II trials, so SHH medulloblastoma is likely to be the 
first subgroup to benefit from targeted therapy. Despite reliable and widely accepted as a 
distinct subgroup, markers for the proper identification of SHH subgroup tumors are still 
needed87. 
 
For the reason that less is known about the biology of the remaining two medullo-
blastoma subgroups, generic names are maintained until a better understanding of the 
underlying driving mechanisms is achieved. 
 
Group 3 
Compared to the other subgroups, Group 3 medulloblastomas have a very poor 
prognosis. Group 3 tumors are more common in males than in females, and are 
observed in infancy and childhood, but very rarly in adults. The reason for restriction of 
Group 3 medulloblastomas to the pediatric age group is unknown. It was suggested that 
the cell of origin for Group 3 tumors is lacking in adults87. Group 3 tumors are more 
similar to Group 4 tumors than to SHH or WNT tumors. Regarding chromosomal 
aberrations, Group 3 medulloblastomas exhibit more frequent loss of both 5q and 10q 
and gain of chromosome 1q than do Group 4 tumors84. Tumors of this subtype indicate 
mostly classic histology, although they enclose the majority of LCA medulloblastoma84,85. 
Additionally, immunopositivity for NPR3 as a Group 3 marker has been suggested as a 
simple diagnostic tool84. No germline mutations predisposing individuals to Group 3 
medulloblastoma have been identified yet87. Group 3 tumors overexpress genes that 
were identified to normally play a role in photoreceptor cells in the retina, and it is 
currently unclear how they affect the pathogenesis of this subset. It has also been 
reported that MYC amplification (but not MYCN amplification) appears to be almost 
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exclusively limited to Group 384,85. Hatten et al. described predominant MYC signaling in 
Group 3 tumors, and therefore suggested to call them the “MYC group” 61. This Subgroup 
is highly associated with unfavorable prognosis due to frequent dissemination at 
diagnosis, and a high risk of recurrence. Indeed, the former usage of metastatic stage as 
a risk factor for poor prognosis identified patient cohorts enriched for Group 3 
medulloblastoma84,87. Therapeutic approaches targeting a transcription factor are difficult 
and small molecule inhibitors of MYC have not been successful in the clinic yet. Up to 
now, no studies on other targets in Group 3 medulloblastomas have been described. 
Existing treatment protocols for high-risk medulloblastoma suggest that doses 
approaching maximal tolerated levels are associated with significant morbidity in these 
patients87. Pei et al. developed recently a MYC driven mouse model for medulloblastoma 
that can be used to test therapies for this devastating disease97,98. 
 
Group 4 
Despite being the most common medulloblastoma subgroup, the underlying biology of 
Group 4 tumors is less well understood. No familial syndromes predisposing individuals 
to Group 4 medulloblastoma have been identified to date. This medulloblastoma sub-
group is found across all age groups, although rarely in infants. It accounts for 25% of 
adult medulloblastomas, often related with a worse prognosis than in childhood cases99. 
Isochromosome 17q is the most common cytogenetic change observed in Group 4 
tumors (66%), although it also appears in Group 3 tumors (26%). Similarly, deletion of 
chromosome 17p occurs often in both Group 3 and Group 4, but practically never in Wnt 
subgroup medulloblastomas. Another prominent cytogenetic change characteristic for 
Group 4 is the loss of the X chromosome, which is seen in about 80% of females having 
Group 4 medulloblastoma (with a male:female ratio of 2:1 in this subgroup)84,100. Roughly 
30% of all medulloblastoma patients have a Group 4 tumor with an intermediate 
prognosis, comparable to patients with SHH tumors. Histologically, Group 4 tumors 
usually belong to the classic variant, although cases of LCA histology have been also 
observed. Only a minority of Group 4 cases exhibits metastases87. Whereas the MYC 
proto-oncogene protein is highly expressed in Group 3 and WNT medulloblastomas, and 
MYCN protein is highly expressed in SHH tumors, Group 4 tumors comprise relatively 
low expression of both MYC and MYCN, apart from a few exceptional cases with MYCN 
amplification61,84,85. Multiple studies identified a representative gene signature of 
processes like neuronal differentiation and development in this subgroup, albeit the 
clinical relevance of this finding is still undetermined84-86. Amplifications of the 
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transcription factor gene OTX2 are restricted to Group 3 and Group 4 medulloblastomas, 
but therapeutics targeting the OTX2 protein have not been described yet87. KCNA1 was 
suggested as a Group 4 marker for immunohistochemical subgroup affiliation83. 
 
1.2.4 Treatment of Medulloblastoma 
Up to now, treatment decisions on medulloblastoma patients are still based on clinical 
parameters such as the histology of the tumor in combination with patient age, presence 
of metastatic disease at primary diagnosis, and extent of resection. According to these 
factors, individuals with medulloblastoma are stratified into risk groups predicting distinct 
response to therapy and prognosis (standard-/low-risk and high-risk). Current multimodal 
treatment protocols for standard- and high-risk medulloblastoma patients include surgical 
resection, different intensities of craniospinal gamma irradiation (17-36 Gy to the 
neuroaxis, 50-55 Gy to the posterior fossa), and varying regimens of chemotherapy101,102. 
To reduce peri-tumoral edema, glucocorticoids (GC) such as dexamethasone are 
frequently used peri-operatively in the management of medulloblastoma. Dosages of 1 
mg/kg are given once daily for a period of 2 to 3 days before surgical intervention. This 
course usually produces a remarkable improvement in the symptoms103.  
Despite therapeutic achievements during the last decades for medulloblastoma patients 
enabling long-term survival rates of 80% in children stratified to standard-risk disease104 
and up to 70% of patients classified to high-risk medulloblastoma105, cure from the 
malignancy is often accompanied with severe side effects. Many survivors experience 
marked intellectual and long-term neurological disabilities secondary to both disease and 
therapy106-109. The increased understanding of medulloblastoma biology and develop-
ment of novel therapies in recent years has not effected the systematic use of empirically 
based treatment regimens, yet. Regarding therapy options, it is necessary to consider 
that medulloblastoma comprises at least four distinct molecular subgroups with entirely 
different clinical and biological features84,85,110. Consequently, to minimize neurological 
damages of the developing brain, especially in infant patients, current treatment 
approaches need to be complemented or even partly substituted by more specific agents 
particularly targeting molecular mechanisms of this malignancy as reviewed by Ellison in 
201053. Identification of such pathomechanisms and further investigation of their 
biological context in medulloblastoma are therefore necessary to improve long term 
effects of patient treatment. 
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1.3 OBJECTIVE	  
Treatment strategies tailored to the clinicopathological and molecular features of 
medulloblastoma are crucial to avoid over- or undertreatment of patients. Since clinical 
and histopathological characteristics do not sufficiently reflect the heterogeneous nature 
of medulloblastoma and accordingly, clinically classified patients might aberrate from the 
actual molecular risk group, ambitious efforts have been put in the identification of 
molecular subgroups. 
 
1.3.1 Chromosome 6q Status Defines Medulloblastoma Subgroups 
In order to provide a more appropriate risk stratification system for medulloblastoma 
patients, transcriptome-based subgrouping, mutation analyses of distinct candidate 
genes as well as specific chromosome aberrations have been identified as potential 
prognostic factors in retrospective cohorts. Pfister et al. recently defined a molecular risk 
stratification model for outcome prediction based on cytogenetic subgroups111. Array-
based karyotyping of 260 medulloblastomas resulted in the following clinical subgroups 
based on DNA-copy number aberrations: (i) poor prognosis: gain of chromosome 6q or 
amplification of MYC/MYCN, (ii) intermediate prognosis: gain of 17q or an i(17q) without 
gain of 6q or amplfication of MYC/MYCN, (iii) excellent prognosis: 6q and 17q balanced 
or 6q deletion. The overall survival probabilities of medulloblastoma patients regarding 
chromosome 6q status are shown in Figure 7. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 Overall survival probabilities for chromosome 6q status. Adapted from Pfister et al.111 
  
	   Introduction 	  	   	  
24 
 
1.3.2 The Candidate Gene SGK1 
The present study aimed at the identification of candidate genes affected by 
chromosome 6q aberrations in medulloblastoma. Serum-glucocorticoid regulated kinase 
1 (SGK1) was identified as a functionally relevant gene in this genomic region. The 
serum-and glucocorticoid inducible serine/threonine kinase SGK1 belongs to the AGC-
kinase family, which is named after its members proteinkinase A, G, and C (PKA, PKG, 
PKC)112,113. AGC-kinases are known to transduce signals of hormones and mitogens, 
thereby mediating a wide range of cellular processes like proliferation and differentiation. 
SGK1 was originally identified in 1993 as a serum- and glucocorticoid-inducible gene in a 
rat mammary tumor cell line114. The SGK1 transcript encodes a protein of about 50kDa 
molecular weight, with an evolutionary highly conserved catalytic domain115. The 
molecular mechanism regulating SGK1 activity has not been fully characterized. 
Structurally, it shares significant homology with PKA, PKB/AKT, PKC, and p70S6 
kinase114. All of these kinases underlie covalent modification by 3- phosphoinositide-
dependent kinase (PDK1)116-119, i.e. the conserved phosphorylation site present in the 
activation loop of these kinases (Thr256 in SGK1) is phosphorylated by PDK1116-119. 
PDK1 is part of the phosphoinositide 3-kinase (PI3K) signaling cascade, which may be 
activated by insulin and other growth factors as e.g. hepatocyte growth factor (HGF), 
insulinlike growth factor-1 (IGF-1), or activation of G-protein coupled receptors, and 
transduce signals by generating the second messengers PI(3,4,5)P3, and PI(3,4)P2. 
Activated PDK1 then phosphorylates SGK1 at Thr256, which leads to a change in 
conformation118. In addition, another phosphorylation site present in a hydrophobic 
domain located in the C-terminus (S422 in SGK1), the so-called PDK2 site, is also 
conserved. Mutation of Ser422 to Ala greatly potentiates SGK1 activation leading to 
constitutive kinase activity at basal levels120,121. Taken together, SGK1 is regulated by the 
phosphorylation of these two sites, which both are necessary for complete activation 
(Figure 8). 
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Figure 8 PI3K pathway and SGK1 activation. Inactive SGK1 is located in the cytoplasm and could be 
associated with the plasma membrane. Stimuli such as hormones, cytokines and amino acids activate the 
receptor tyrosine kinases (RTK) or G protein-coupled receptors (GPCR) on the cell surface. PI3Ks are 
recruited to the membrane in order to phosphorylate phosphatidylinositol (PI) for the generation of 
phosphatidylinositol(3,4,5)-triphosphates (PIP3). This process is reversible by phosphatase and tensin 
homologue (PTEN). PIP3s recruit PDK1, which activates SGK1 by binding to the hydrophobic motif (HM) 
and phosphorylates the activation loop. Modified from122. 
 
Human SGK1 was for the first time described in 1997 as a gene being upregulated in 
response to changes in cell volume123. It has been shown that the subcellular distribution 
of SGK1 is dependent on both cell cycle and hormonal regulation, which correlates with 
the phosphorylation state of the protein124 suggesting that SGK1 expression and activity 
serves as an integration point for several signaling pathways. SGK1 has significant 
consensus substrate sites in its catalytic domain that are generally similar to those of the 
anti-apoptotic kinase PKB/AKT, suggesting some overlap in protein substrates120,121. 
SGK1 has been shown to phosphorylate glycogen synthase kinase-3 (GSK-3), Raf 
kinase, and the forkhead family member FOXO3a in vitro 120,125, which are also targets of 
the AKT protein kinase, although to date the identification of SGK1 substrates in vivo 
have remained elusive126. AKT proteins include lipid-binding pleckstrin homology (PH) 
domains at the N-terminus, while the closely related SGK1 lacks this domain127. 
 
SGK1 activity is tightly balanced on three regulation levels: mRNA expression, protein 
phosphorylation and protein degradation. In contrast to many other kinases, SGK1 
transcription is strictly regulated128. Moreover, phosphorylation at two sites is indis-
pensable for full kinase activity, and the mRNA transcript, as well as the protein have a 
very short half-life114,129. Induction of mRNA expression occurs within a couple of minutes 
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after an adequate stimulus114, whereas the transcript has a half-life of only about 20 
minutes, therefore belonging to the most transient mRNA species114. On transcriptional 
levels, SGK1 has been shown to be upregulated upon dexamethasone treatment due to 
activation of the glucocorticoid receptor130. A glucocorticoid response element (GRE) has 
been identified within the SGK1 promoter114,126,131,132. Since SGK1 transcription is also 
induced by serum, certain properties of the blood serum are supposed to induce SGK1. 
Indeed, there is evidence for several factors and hormones influencing SGK1 gene 
expression, e.g. follicle-stimulating hormone (FSH), transforming growth factor-β (TGF-
β), granulocyte macrophage colony-stimulating factor (GM-CSF), fibroblast growth factor 
(FGF), platelet derived growth factor (PDGF) and tumor necrosis factor-α (TNF-α) were 
shown to upregulate SGK1 expression133-137. Besides hormones and growth factors, a 
series of studies revealed that SGK1 is also under control of a variety of environmental 
stresses, like UV irradiation, heat shock, oxidative stress, and hyperosmotic stress115. 
 
The SGK1 protein has a half-life of less than 30 minutes, which is tightly regulated by 
polyubiquitination-dependent proteasomal degradation129. Ubiquitinated SGK1 protein is 
mainly located at the membrane, whereas the non-ubiquitinated protein is found in the 
cytoplasma, nucleus and the endoplasmatic reticulum (ER)124,138. The sequence 
encoding the ubiquitination signal is located in the first 60 amino acids in the N-
terminus129,139. The E3 ubiquitin ligase Nedd4-2 is involved in this process140. An 
evolutionarily conserved N-terminal SGK1 variant with enhanced stability and improved 
function has been described recently, which is characterized by increased half-life due to 
reduced ubiquitinylation141. The very short half-life of both, SGK1 mRNA and protein 
leads to the problem, that baseline SGK1 protein is marginally detectable in many 
conditions despite of high mRNA expression. 
 
Threonine residues in the N-myc downstream-regulated gene 1 protein (NDRG1-Thr-
346/-356/-366) are phosphorylated by SGK1 but not by related kinases142. Therefore 
these phosphorylation sites of NDRG1 specifically indicate SGK1 activity143. 
 
1.3.3  (Patho-) Physiological Role of SGK1  
SGK1 is physiologically expressed in several tissues, including the pancreas, skeletal 
muscle, liver, heart, placenta, kidney and brain123,144. In the brain, SGK1 mRNA 
transcripts have been found besides neurons mainly in oligodendrocytes and microglia 
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cells145,146. Sgk1 knockout (sgk1-/-) mice are vital and no obvious phenotype due to the 
gene inactivation has been found147,148. The functional role of SGK1 has been 
extensively studied mostly with regard to physiological regulation of metabolism, kidney 
function, blood pressure, and salt appetite115,149. Furthermore, there are various patho-
physiological implications of SGK1 in metabolic diseases (e.g. diabetes mellitus, 
metabolic syndrome, hypertension, diabetic nephropathy150-153, inflammatory diseases 
(e.g. liver cirrhosis, lung fibrosis, rheumatism), as well as in neurodegenerative diseases 
(e.g. Chorea Huntington, Morbus Parkinson)154-156. The implication of SGK1 in tumori-
genesis has been found in various solid tumors including breast cancer, prostate-, 
colorectal-, as well as hepatocellular carcinomas157-161. Several reports suggested a 
functional role of SGK1 in tumor biology by promoting cell survival and cell-cycle 
progression. A first hint towards affecting cell-cycle progression was the finding that 
SGK1 translocates from the cytoplasm to the nucleus upon growth factor or hormone 
stimulation depending on the cell-cycle phase124,162. In breast cancer cell lines, activated 
SGK1 negatively regulates stress-activated JNK signaling by targeting SEK1163. 
Moreover, SGK1 contributes to cell survival, cell-cycle progression, and epithelial de-
differentiation via MDM2-dependent p53 ubiquitinylation164. In addition, anti-apoptotic 
effects of SGK1 were shown to be mediated via activation of nuclear factor κB (NF-κB) 
signaling due to increased degradation of the NF-κB inhibitor IκB165. Furthermore, in 
kidney cancer cells, apoptosis signaling was shown to be inhibited by interleukin-2 (IL-2) 
through regulation of SGK1 at transcriptional and post-transcriptional levels166. SGK1 
was described to function complementary to the anti-apoptotic kinase AKT in promoting 
cell survival by directly phosphorylating and inactivating the pro-apoptotic proteins 
forkhead transcrition factor FKHRL1 (FOXO3a) and BCL2-associated agonist of cell 
death (BAD)167,168. By phosphorylating FOXO3a in neuronal cells, SGK1 promotes its 
export from the nucleus and thereby inhibits its pro-apoptotic function125. Moreover, 
activated SGK1 has been shown to block apoptosis induced by loss of integrin-mediated 
cell attachment (anoikis169) by preventing de-attachment-induced dephosphorylation of 
FOXO3a in canine kidney epithelial cells (MDCK)168. SGK1 has been identified as a 
mTORC1 (mTOR-raptor) substrate. Thus, mTOR may promote G1 progression in part 
through SGK1 activation and deregulate the cell cycle in cancers through both AKT- and 
SGK1-mediated p27 phosphorylation and cytoplasmic p27 mislocalization170. A recent 
report implicated another possible mechanism for the role of SGK1 in cancer formation, 
in which SGK1 was described as target gene of the WNT-signaling pathway. Thereby, 
elevated SGK1 phosphorylation was associated with predominant SGK1 localization to 
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the cytosol, inactivation of GSK3ß via phosphorylation by SGK1 and finally exclusion of 
GSK3ß from the nucleus, resulting in increased c-MYC stabilization171. It was 
demonstrated that SGK1 expression favors the spontaneous development of intestinal 
tumors in APC deficient mice regarding apc(Min/+)/sgk1(+/+)mice, which exhibit 
significantly more tumors than apc(Min/+)/sgk1(-/-)mice172. Finally, a study following 
chemical carcinogenesis, confirmed that sgk1(-/-) mice developed significantly less 
colonic tumors than their wild type littermates sgk1(+/+)173. Protection from apoptosis and 
increased chemotherapy resistance upon glucocorticoid treatment has been found in a 
broad variety of solid cancers including brain tumors. It was shown that dexamethasone 
treatment inhibits cisplatin and 5-fluorouracil-induced apoptosis and promotes the growth 
of the malignant cells174. This phenomenon is associated with a glucocorticoid receptor-
dependent, transcriptional induction of anti-apoptotic genes, including SGK1, which also 
protects breast cancer cells from growth factor starvation-induced apoptosis130,175. 
 
1.4 AIMS	  OF	  THE	  STUDY	  
Integrative DNA copy-number analysis and transcriptome profiling focusing on genes 
located on chromosome 6q identified SGK1 as a promising candidate gene in medullo-
blastoma with clear subgroup-specific expression. This was further substantiated by the 
immunohistochemical examination of SGK1 in an independent large cohort of medullo-
blastoma revealing SGK1 protein expression as a potential new prognostic biomarker. 
Consequently, functional analyses in vitro were conducted to investigate the implication 
of SGK1 in medulloblastoma biology and pathogenesis. 
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2 MATERIALS	  &	  METHODS	  
2.1 MATERIALS	  
2.1.1 Antibodies 
Target Source Dilution Supplier 
NDRG1 Goat 1:2500 Abcam, Cambridge, UK 
NDRG1 (pT346)  Rabbit 1:1000 Cell signaling, Danvers, USA 
SGK1 Rabbit 1:1000 Abcam, Cambridge, UK 
SGK1 Rabbit 1:100 Pineda, Berlin, Germany 
ß-ACTIN Mouse 1:1000 Santa Cruz Biotechnology, Santa 
Cruz, USA 
Goat (HRP-coupled)  Donkey 1:5000 Santa Cruz Biotechnology, Santa 
Cruz, USA 
Mouse (HRP-coupled) Goat 1:5000 Santa Cruz Biotechnology, Santa 
Cruz, USA 
Rabbit (HRP-coupled) Goat 1:3000 Cell Signaling, Danvers, USA 
 
2.1.2 Biochemicals and Reagents 
Substance	   Supplier	  
7AAD, 7-aminoactinomycin 	  BD	  Bioscience,	  Heidelberg,	  Germany	  
ABsolute™ QPCR SYBR® Green Mixes ABgene,	  Epsom,	  UK	  
Acrylamide/bis-acrylamide Roth, Karlsruhe, Germany 
Agarose Sigma Aldrich, Munich, Germany 
Ammonium acetat 7.5M Sigma-­‐Aldrich,	  Munich,	  Germany	  
Ammoniumpersulfate (APS) Roth, Karlsruhe, Germany 
Ampicillin Roche Diagnostics, Mannheim, Germany 
AnnexinV binding buffer (10x) BD	  Bioscience,	  Heidelberg,	  Germany	  
AnnexinV-PE BD	  Bioscience,	  Heidelberg,	  Germany	  
Bacto Agar Difco Laboratories, Detroit, USA 
Bacto tryptone Difco Laboratories, Detroit, USA 
Bacto yeast extract Difco Laboratories, Detroit, USA 
Bicinchonic acid (BCA) Sigma Aldrich, Munich, Germany 
Boric acid Roth,	  Karlsruhe,	  Germany	  
Bovine serum albumine (BSA) Sigma-­‐Aldrich,	  Munich,	  Germany	  
Bromophenole blue AppliChem, Darmstadt, Germany 
Chloroform Merck,	  Darmstadt,	  Germany	  
  
	   Materials & Methods 	  	   	  
30 
Complete Mini protease inhibitors Roche Diagnostics, Mannheim, Germany 
Copper-(III)-sulfate Sigma Aldrich, Munich, Germany 
Copper-II sulfate Roth,	  Karlsruhe,	  Germany	  
Cyanine 3-CTP (Cy3) Perkin	  Elmer,	  Boston,	  USA	  
Cyanine 5-CTP (Cy5) Perkin	  Elmer,	  Boston,	  USA	  
Desoxynukleotid (dNTP)-Set 100 mM Fermentas,	  St.	  Leon-­‐Rot,	  Germany	  
Dimethylsulfoxide (DMSO) Sigma Aldrich, Munich, Germany 
Dithiothreitol (DTT) Sigma Aldrich, Munich, Germany 
DNA Loading Dye Fermentas,	  St.	  Leon-­‐Rot,	  Germany	  
DNA Pol Puffer 1 Roche	  Diagnostics,	  Mannheim,	  Germany	  
ECL (plus) substrate GE Healthcare, München, Germany 
EDTA 25 mM Invitrogen,	  Karlsruhe,	  Germany	  
Ethanol Merck, Darmstadt, Germany 
Ethidium bromide Sigma Aldrich, Munich, Germany 
Ethylenediaminetetraacetic acid (EDTA) Merck, Darmstadt, Germany 
First Strand Buffer Invitrogen,	  Karlsruhe,	  Germany	  
Formalin/PBS (10% v/v) Sigma Aldrich, Munich, Germany 
Formamide Merck,	  Darmstadt,	  Germany	  
Gene Ruler™ 1 kb DNA ladde Fermentas,	  St.	  Leon-­‐Rot,	  Germany	  
Glycerol Roth, Karlsruhe, Germany 
Glycine Roth, Karlsruhe, Germany 
Hydrochloric acid (HCL) Merck, Darmstadt, Germany 
LPA (linear polyacrylamide) Ambion,	  Austin,	  USA	  
Methanol Merck, Darmstadt, Germany 
NEB buffer 4 (10x) New England Biolabs, Frankfurt, 
Germany 
Nuclease free water Ambion, Austin, USA 
Oligo-(dT)20 primer Invitrogen,	  Karlsruhe,	  Germany	  
PE annexin V BD,	  Heidelberg,	  Germany	  
Phenylmethylsulfonylfluorid (PMSF) Sigma-­‐Aldrich,	  Munich,	  Germany	  
Potassium chloride (KCl) Sigma-­‐Aldrich,	  Munich,	  Germany	  
Potassium dihydrogen phosphate (KH2PO4) Carl	  Roth,	  Karlsruhe,	  Germany	  
Propidium iodide Sigma Aldrich, Munich, Germany 
RNAse-free wate Ambion,	  Austin,	  USA	  
SOC medium Invitrogen, Karlsruhe, Germany 
Sodium acetate (NaAc) Roth,	  Karlsruhe,	  Germany	  
Sodium borate Merck,	  Darmstadt,	  Germany	  
Sodium chloride (NaCl) Merck,	  Darmstadt,	  Germany	  
Sodium citrate Merck, Darmstadt, Germany 
Sodium dodecyl sulfate (SDS) Sigma Aldrich, Munich, Germany 
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Sodium fluoride (NaF) Roth,	  Karlsruhe,	  Germany	  
Sodium hydrogenphosphate (Na2HPO4) Sigma-­‐Aldrich,	  Munich,	  Germany	  
Sodium hydroxide (10 M) Sigma-­‐Aldrich,	  Munich,	  Germany	  
Sodium orthovanadate Roth,	  Karlsruhe,	  Germany	  
Spectra multicolor broad range protein 
ladder 
Fermentas,	  St.	  Leon-­‐Rot,	  Germany	  
Stratagene human reference RNA Stratagene,	  La	  Jolla,	  USA	  
T4 gene 32 protein USB,	  Cleveland,	  USA	  
Tetramethylethylenediamine (TEMED) Roth, Karlsruhe, Germany 
Tris-base Sigma Aldrich, Munich, Germany 
Tris-hydrochloride Roth,	  Karlsruhe,	  Germany	  
Triton X-100 Sigma Aldrich, Munich, Germany 
Trizol reagent Invitrogen,	  Karlsruhe,	  Germany	  
Tween 20 Sigma Aldrich, Munich, Germany 
Whole milk powder Roth, Karlsruhe, Germany 
β-Mercaptoethanol Biorad,	  Hercules,	  USA	  
 
2.1.3 Buffers and Solutions 
Solution Composition 
Blocking solution 10% milk/3% BSA in TBS-T 
FACS buffer  0.1%BSA, 0.02%Azide in 1xPBS 
Laemmli-buffer (5x) 8 % SDS, 200 mM Tris, 0.08 % bromphenol 
blue, 40 % glycerol, 10 % 2-mercaptoethanol, 
pH 6.8 
LB-medium 10g Bacto tryptone/peptone, 5g Bacto yeast 
extract, 10g NaCl, ad 1L dd H2O 
Nicoletti buffer 0.1% sodium citrate, 0.1% Triton X-100, 
50μg/ml PI 
Phosphate buffered saline (PBS) 137 mM NaCl, 2.7 mM KCl, 9.2 mM Na2HPO4, 
1.8 mM KH2PO4, pH 7.4 
Protein-lysis buffer (1x) RIPA buffer, 10 mM NaF, 1 mM sodium 
orthovanadate, 10 mM phenylmethyl-
sulfonylfluorid (PMSF), 1 x Mini Protease 
Inhibitor Cocktail 
RIPA buffer (1x) 150 mM NaCl, 1.0% Nonidet P-40, 0.5% 
sodium deoxycholate, 0.1% SDS, 50 mM Tris, 
pH 8.0 
SDS-PAGE buffer (1x) 25 mM Tris, 200 mM glycine, 0.5% SDS, pH 
8.8 
TE-buffer (Tris-EDTA)  10 mM Tris-HCl, 1 mM EDTA, pH 8.0 
Transfer buffer (1x) 25 mM Tris, 200 mM glycine, 20 % methanol, 
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pH 8.8 
Tris buffered saline (TBS) (1x) 150 mM NaCl, 10 mM Tris, pH 7.4 
Tris buffered saline Tween20 (TBS-T) 150 mM NaCl, 10 mM Tris, 0.05% (v/v) 
Tween20, pH 7.4 
Tris-borate-EDTA (TBE) (1x) 89 mM boric acid, 89 mM Tris-base, 2 mM 
EDTA,pH 8.0 
Tris-Glycine SDS running buffer (1x) 25 mM Tris, 192 mM Glycine, 0.1% SDS, pH 
8.3 
Western Blot stripping solution 62.5 nM Tris-HCl, 2% SDS, 200 nm 2-
mercaptoethanol, pH 6.7 
 
2.1.4 Cell Culture Reagents 
Reagent Supplier 
DMEM (Dulbecco´s Modified Eagle 
Medium); 4500 mg/L glucose 
Gibco BRL/Invitrogen, Karlsruhe, Germany 
Fetal Calf Serum (FCS)  Biochrom AG, Berlin, Germany 
L-glutamine Gibco Invitrogen, Karlsruhe, Germany 
MEM alpha  Gibco BRL/Invitrogen, Karlsruhe, Germany 
OptiMEM Gibco Invitrogen, Karlsruhe, Germany 
Penicillin/Streptomycin (1000 U/ml) Gibco Invitrogen, Karlsruhe, Germany 
Phosphate Buffered Saline Gibco Invitrogen, Karlsruhe, Germany 
Polybrene Millipore, Billerica, USA 
Polyethylenimine Polyscience, Niles, USA 
Puromycin (10 mg/ml)  Invitrogen, Karlsruhe, Germany 
TransIT-293 transfection reagent Mirus	  Bio,	  Madison,	  USA 
Trypsin/EDTA (0.05%w/v) Invitrogen, Karlsruhe, Germany 
 
2.1.5 Cell Lines and Bacterial Strains 
Cell line Origin Acc.-No. Supplier/Source 
D283 MED Human medulloblastoma HTB-185 ATCC, Manassas, USA 
Daoy Human medulloblastoma HTB-186 ATCC, Manassas, USA 
HEK293T Human embryonic kidney CRL-1273 ATCC, Manassas, USA 
MED8A Human medulloblastoma provided by Michael Taylor, Toronto, USA 
OneShot TOP10 competent E.coli Invitrogen, Karlsruhe, Germany 
ONS-76 Human medulloblastoma provided by Michael Taylor,Toronto, USA 
UW228-2 Human medulloblastoma provided by Steve Clifford, Newcastle, UK 
UW228-3 Human medulloblastoma provided by Steve Clifford, Newcastle, UK 
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2.1.6 Drugs 
Substance Supplier 
4-hydroxycyclophosphamide (4-HC) Niomech, Bielefeld, Germany 
Dexamethasone Sigma-Aldrich, München, Germany 
GSK650394 (by GlaxoSmithKline) Oncology R&D; Collegeville, USA 
Lomustine (CCNU)  Medac, Wedel, Germany 
 
2.1.7 Enzymes 
Enzyme Supplier 
Cla I New England Biolabs, Ipswitch, USA 
DNase Shrimp recombinant USB Corporation, Cleveland, USA 
GoTaq DNA polymerase Promega, Mannheim, Germany 
Not I New England Biolabs, Ipswitch, USA 
Precisor Polymerase Biocat, Heidelberg, Germany 
RNase H Qiagen, Hilden, Germany 
SuperScriptII reverse transcriptase Invitrogen, Karlsruhe, Germany 
T4 DNA Ligase Roche Diagnostics, Mannheim, Germany 
Taq DNA Polymerase Qiagen, Hilden, Germany 
XbaI Fermentas, St. Leon Rot, Germany 
XhoI New England Biolabs, Frankfurt, Germany 
 
2.1.8 Instruments 
Instrument Supplier 
ABI PRISM 7900 Sequence Detection 
System 
Applied Biosystems, Foster City, USA 
Agilent 2100 Bioanalyzer  Agilent Technologies Inc., Santa Clara, USA 
Agilent DNA Microarray Scanner 
G25505B  
Agilent Technologies Inc., Santa Clara, USA 
Axioskop 40 microscope Carl Zeiss, Jena, Germany 
Biofuge Fresco Heraeus Instruments, Hanau, Germany 
EL800 Universal Microplate Reader Bio-Tek instrum., Bad Friedrichshall, Germany 
Eppendorf Mastercycler Gradient Eppendorf, Hamburg, Germany 
FACSCanto II BD Biosciences, San Jose, USA 
Gel electrophoresis power supply E-C Apparatus Corporation, Holbrook, USA 
Heating block QBT Grant Instruments, Cambridge, UK 
HMT 702 C microwave oven  Robert Bosch GmbH, Stuttgart, Germany 
Hybridisation Oven  Agilent Technologies, Santa Clara, USA 
Incubator Thermo Forma Thermo Fisher Scientific, Langenselbold, 
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Germany 
Leica DM IRB/E inverted microscope 
system  
Leica, Wetzlar, Germany 
L8-M Ultracentrifuge Beckmann Coulter GmbH, Krefeld, Germany 
Mini Protean gel electrophoresis 
system 
BioRad, Munich, Germany 
NanoDrop ND-1000 spectrometer NanoDrop, Wilmington, USA 
Pipettes  Gilson, Middleton, USA 
Sterile bench Hera Safe  Thermo Fisher Scientific, Langenselbold, 
Germany 
Unimax 1010 Shaker  Heidolph Instruments, Schwabach, Germany 
UV Gel Documentation BioRad, Hercules, USA 
Vakuumcentrifuge (Concentrator 
5301) 
Eppendorf, Hamburg, Germany 
Varifuge 3.0 Heraeus Instruments, Hanau, Germany 
Vi-CELL XR 2.03 Beckman Coulter, Krefeld, Germany 
Vortex mixer Neo lab 7-2020, Heidelberg, Germany 
Water bath SW22 Julabo Labortechnik, Seelbach, Germany 
 
2.1.9 Materials 
Material Supplier 
96well microtiter plates with flat bottom Nunc, Wiesbaden, Germany 
ABI PRISM optical adhesive covers Applied Biosystems, Foster City, USA 
Agilent RNA Nano Chip  Agilent Technologies, Santa Clara, USA 
Blotwet gel transfer system Biorad, Hercules, USA 
Cell culture flasks Corning, New York, USA 
FACS tubes BD Bioscience, Heidelberg, Germany 
Falcon transwell inserts (8 μm pores) BD Biosciences, Heidelberg, Germany 
Falcon tubes (15ml and 50ml) BD Bioscience, Heidelberg, Germany 
FUJI Medical X-ray films, Super RX FUJIFilm, Tokyo, Japan 
Gradient gels 4-20% (Tris-glycine); Lonza 
PAGEr* Gold Precast Gels 
LONZA, Basel, Switzerland 
Kryo-tubes (1.8 ml)  Nunc, Wiesbaden, Germany 
Microtiter plates (384 well)  Steinbrenner Laborsyst., Wiesenbach, 
Germany 
Mini Trans-Blot wet gel transfer apparatus BioRad, Hercules, USA 
RIPA buffer Sigma-Aldrich, Munich, Germany 
PCR tubes (0.2ml) Molecular BioProducts, San Diego, USA 
Pipette tips (10 μl; 20 μl; 100 μl; 1000μl)  Starlab, Ahrensburg, Germany 
Polyvenylidene fluoride membrane 
(PVDF) 
Sigma-Aldrich, Munich, Germany 
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Reaction tubes Safe-lock (1.5 ml; 2 ml) Eppendorf, Hamburg, Germany 
RNase ZAP Ambion, Austin, USA 
Syringe Millex-HA filters 0.45 µm Millipore, Billerica, USA 
Tissue culture plates (24 well) Nunc, Wiesbaden, Germany 
Tissue culture plates (6 well)  Nunc, Wiesbaden, Germany 
Whatman paper  Sigma-Aldrich, München, Germany 
 
2.1.10 Molecular Biology Kits 
Kit Supplier 
ABsolute QPCR SYBR® Green Mix  Abgene, Epsome, UK 
BigDye Terminator Sequencing kit Applied Biosystems, Foster City, USA 
CloneJet PCR cloning kit Fermentas, St. Leon-Roth, Germany 
ECL Western Blot detection kit GE Healthcare, Munich, Germany 
QiaPrep maxiprep kit Qiagen, Hilden, Germany 
QiaPrep spin miniprep kit Qiagen, Hilden, Germany 
QiaQuick gel extraction kit Qiagen, Hilden, Germany 
Rapid DNA dephos & ligation kit Roche Diagnostics, Mannheim, Germany 
RNA 6000 Nano kit Agilent Technologies Inc., Santa Clara, USA 
RNeasy Mini kit Qiagen, Hilden, Germany 
SuperScriptII RT Kit Invitrogen, Karlsruhe, Germany 
ViCell XR reagent pack Beckmann Coulter GmbH, Krefeld, Germany 
Whole Human Genome Microarray  
kit, 4x44K  
Agilent Technologies Inc., Santa Clara, USA 
 
2.1.11 Plasmids and shRNAs 
Plasmid/shRNA Supplier 
MISSION shRNA SGK1 
NM_005627; E7-11; C2; C4 
Sigma-Aldrich, München, Germany 
pJet1.2 blunt vector Fermentas, St- Leon-Roth, Germany 
pLKO.1-Puro TRC 1.5 Sigma-Aldrich, München, Germany 
pLKO.1-Puro TurboGFP Sigma-Aldrich, München, Germany 
pLVX-Puro Clontech, Mountain View, USA 
pLVX-Puro AcGFP Clontech, Mountain View, USA 
pMD2.G Addgene, Cambridge, USA 
psPAX2 Addgene, Cambridge, USA 
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2.1.12 Primers 
Primer Seqence (5´à 3´) 
ClaI_SGK1_HA AATCGATTCAAGCGTAATCTGGAACATCGTA
TGGGTAGAGGAAAGAGTCCGTGGGA 
DCTN2 fwd CGCCATGGCGGACCCTAAAT 
DCTN2 rev TTGTCAGCTCCTCCGCATCGAA 
LMNB1 fwd GCTCCTCAACTATGCTAAGAA 
LMNB1 rev TCTTTCGAATTCAGTGCTGCTTC 
NotI_SGK1_fwd GCGGCCGCATGACGGTGAAAACTGAGGC 
PGK1 fwd AAGTGAAGCTCGGAAAGCTTCTAT 
PGK1 rev AGGGAAAAGATGCTTCTGGG 
pJET1.2 seq fwd CGACTCACTATAGGGAGAGCGGC 
pJET1.2 seq rev AAGAACATCGATTTTCCATGGCAG 
pLVX-Puro seq fwd CCTGGAGACGCCATCCACGC 
pLVX-Puro seq rev ACTTGTGTAGCGCCAAGTGC 
PPIA fwd CGCCATGGCGGACCCTAAAT 
PPIA rev GCAAACAGCTCAAAGGAGACG 
SGK1 fwd TGGCACGCCGGAGTATCTCGCA 
SGK1 rev AAGACAGCTCCCAGGCACCACC 
SGK1fwd_TQStevens353 GACTGTGGACTGGTGGTG 
SGK1rev_TQStevens353 CAGGCTCTTCGGTAAACT 
 
2.1.13 Software and Databases 
Software/Database Supplier/Source 
Adobe Photoshop CS2 Adobe, Dublin, Rep. of Ireland 
Agilent Expert 2100  Agilent Technologies, Santa Clara, USA 
BD FACS DivaTM BD Biosciences, San Jose, USA 
BLAST  http://www.ensembl.org/Multi/blastview/ 
http://www.ncbi.nlm.nih.gov/BLAST/ 
ChipYard© http://www.dkfz.de/genetics/ChipYard/ 
ClustalW2;  
Multiple Sequence Alignment 
http://www.ebi.ac.uk/Tools/msa/clustalw2/ 
EnsEMBL  http://www.ensembl.org/index.html 
Feature Extraction 9.1  Agilent Technologies, Santa Clara, USA 
Gap4/ Pregap4 Staden Package MRC Laboratory of Molecular Biology, 
Cambridge, UK 
Gene Ontology terms http://www.geneontology.org/ 
GeneCards V3 http://www.genecards.org/ 
GenePix Pro Version 6.0  Axon Instruments Inc., Union City, USA 
GraphPad Prism 5.0 GraphPad Software Inc. La Jolla, USA 
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KC Junior  Bio-Tek, Bad Friedrichshall, Germany 
KEGG pathways http://www.genome.jp/kegg/pathway.html 
Microsoft Excel 2007  Microsoft, Redmond, USA 
Microsoft Powerpoint 2007  Microsoft, Redmond, USA 
Microsoft Windows  Microsoft, Redmond, USA 
MSigDB v3.0 (Broad Institute’s 
Molecular Signatures Database)  
http://www.broadinstitute.org/gsea/msigdb/ 
index.jsp 
NCBI  http://www.ncbi.nlm.nih.gov/ 
OligoCalculator http://www.basic.northwestern.edu/biotools/ 
oligocalc.html 
PIMS©  http://www.dkfz.de/en/genetics/pages/ 
projects/bioinformatics/PIMS.html 
PubMed  http://www.ncbi.nlm.nih.gov/pubmed 
PubMed  http://www.ncbi.nlm.nih.gov/pubmed/ 
R 2.2.1 Open source http://www.r-project.org/ 
R2; microarray analysis and 
visualization platform  
http://hgserver1.amc.nl/cgi-bin/r2/main.cgi 
RankProd  http://bioinformatics.oxfordjournals.org/content/2
2/22/2825.full 
SDS 2.2.2™ Applied Biosystems, Foster City, USA 
UCSC Genome Browser http://genome.ucsc.edu/ 
 
2.2 MOLECULAR	  BIOLOGY	  METHODS	  
2.2.1 DNA Procedures 
2.2.1.1 Plasmid-DNA Preparation from E.coli 
For isolating recombinant generated plasmid-DNA from transformed bacteria (see 
section 2.2.1.2), plasmid QIAprep kits (spin Miniprep, Maxiprep; Qiagen, Hilden, 
Germany) were used. Therefore, transformed E.coli cell clones were grown in LB-media 
containing Ampicillin for selection, over night at 37°C on a bacteria shaker. Following 
centrifugation at 4000rpm at 4°C, the bacteria pellet was lysed under alkaline conditions 
according to the manufacturer´s protocol. The alkaline SDS containing buffer from the kit 
leads to denaturation of bacterial DNA and proteins. After subsequent neutralisation and 
high salt concentrations, the denaturated genomic DNA and proteins were precipitated 
and seperated from plasmid DNA by centrifugation. Circular plasmid DNA remained in 
the supernatant and was purified using colums with silica-membranes. Finally, plasmids 
were eluated in 50 μl EB buffer and sequenced using Sanger method (see section 
2.2.1.3). 
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2.2.1.2 Cloning 
C-terminally HA-tagged SGK1 was generated by amplification of SGK1 (Entrez Gene ID: 
6446) from a plasmid pDONR223 kindly provided by Core Facility, DKFZ, Heidelberg. 
The gene was amplified with Primers NotI_SGK1_for and ClaI_SGK1_HA for including a 
HA-tag directly in front of the stop-codon using Precisor proofreading polymerase 
(Biocat) according to manufacturer´s protocol. The calculated primer melting temperature 
of the region complementary to the SGK1 sequence (irrespective of additional restriction 
enzyme cleavage site and HA-tag) annealing temperature of the PCR was adjusted to 
58°C. After amplification in 35 cycles, PCR products were separated by agarose gel 
electrophoresis and extracted with QIAquick gel extraction kit (Qiagen). Amplicons were 
inserted into pJet1.2/blunt plasmid using the CloneJet PCR cloning kit (Fermentas). After 
transformation of OneShot TOP10 competent E. coli cells (Invitrogen), colony-PCR, 
culturing and plasmid preparation (Qiagen Plasmid Midi Kit), sequences were verified by 
Sanger sequencing using plasmid-internal primers (pJet1.2 fwd, rev). Subsequently, pJet 
plasmids containing the SGK1-HA construct and pLVX-Puro plasmid (Clontech, 
Mountain View, USA) (Figure 9 B) were double-digested with XhoI and XbaI restriction 
enzymes (10 U each, Biolabs) for 2h at 37°C, enzyme inactivation 15 mins at 65°C. 
Digested constructs were separated by preparative agarose gel electrophoresis (0.8%) 
and inserts and linearized target vector were gel extracted and dissolved in water for 
subsequent ligation. For ligation with T4 ligase (Roche) reaction mix was prepared and 
vector and insert was added in a ratio 1:3 molecules. Ligation was incubated at 4°C over 
night and then used for transformation of chemically competent OneShot TOP10 
Escherichia coli (E.coli). Subsequent to the cloning procedures, transformed E.coli were 
grown on selective agar plates containing 100 μg/ml ampicillin. After over night 
incubation, grown colonies were used for inoculation of Luria-Bertani (LB) medium mini 
cultures containing 100 μg/ml ampicillin and incubated over night. Plasmids were 
extracted from cultures using QIAprep Spin Miniprep Kit (Qiagen). The sequence of the 
cloned gene was verified by Sanger sequencing using plasmid specific primers (pLVX-
Puro fwd, rev) and BigDye Terminator v3.1 Cycle Sequencing Kit. 
 
The pLVX-Puro vector is compatible with the lentiviral system of 2nd generation for virus 
production (see section 2.2.3.2). The transgene SGK1-HA was cloned downstream of 
the constitutive active CMV promoter located on the pLVX-Puro backbone (Figure 9 B) 
allowing strong gene expression. The plasmid contains besides the pUC Ori for bacterial 
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replication and the resistance gene Ampr for ampicillin selection additionally a viral cis-
element between the 5´ and 3´ UTR. RRE (rev response element) binding site enhances 
virus titers by exporting the RNA of the gene expression cassette outside from the 
nucleus during virus production. In contrast, the central polypurinetract (cPPT) enhances 
the import oft he transgene into the nucleus oft he transduced host cell. Moreover, 
WPRE (woodchuck hepatitis virus posttranscriptional regulatory element) is another 
regulatory element of the vector supporting processing and maturation of viral transcrips 
and enhances the export from the nucleus which increases further the lentivirus titers. 
 
 
Figure 9 Vector maps of plasmids for producing recombinant lentiviruses. A) pLKO.1-puro TRC1.5 
plasmid (Sigma-Aldrich) for RNA interfering experiments. B) pLVX-puro vector (Clontech) for transgenic 
overexpression of SGK1. Adapted from the manufacturer´s protocols176,177. 
 
2.2.1.3 Sanger Sequencing 
Purified PCR products or plasmid DNA were sequenced using the BigDye Terminator 
v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, USA) including thermally 
stable AmpliTaq DNA polymerase, modified deoxynucleoside triphosphates (dNTP) and 
a set of dye terminators labelled with high-sensitivity dyes. 10-20ng purified PCR product 
or 250ng plasmid DNA at a volume of 6.7μl was employed in a mixture (prepared on ice) 
containing 3μl BigDye, 0.3μl sequence-specific primer as used for the amplification-PCR 
(10μM), and filled up with ddH2O to a final volume of 10μl. After running the sequencing 
PCR (3 mins initial denaturation at 96°C, followed by 25 cycles of 30 sec denaturation at 
96°C, 15 sec annealing at 51°C, 4 mins extension at 60°C), samples were precipitated. 
The sequencingmixture was added to 1μl 3M sodium acetate (pH 5.2; Roth, Karlsruhe, 
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Germany) and 24μl absolute ethanol, centrifuged at 13000rpm for 30min, washed with 
200μl ethanol (70%) and centrifuged again at 13000rpm for 15min. After discarding the 
supernatant, the pellets were dried, resuspended in 10μl formamide (Applied 
Biosystems, Foster City, USA) and finally sequenced on an ABI PRISM 3100 Genetic 
Analyzer (Applied Biosystems, Foster City, USA). 
 
2.2.1.4 Array-based Comparative Genomic Hybridization 
The procedure of array-based comparative genomic hybridization (array-CGH)178 shall 
be mentioned only in outlines here. Selection of genomic clones, isolation of BAC 
(bacterial artificial chromosome) DNA, conducting of degenerative oligonucleotide-
priming PCR and spotting of PCR products on microarrays were conducted as previously 
described179,180. Genomic DNA was isolated from tumor tissue as well as from blood of 
healthy donors using the Qiagen DNA Blood&Tissue Kit (Qiagen). DNA of the tumor 
sample as well as gender-matched reference DNA (pooled DNA from several healthy 
individuals) were labeled with different fluorescent color dyes by use of the Bioprime 
Labeling Kit (Invitrogen). Labeled tumor and reference DNA were precipitated together 
with unlabeled Cot-1 DNA (Roche) enriched for repetitive DNA sequences in order to 
suppress cross hybridization events and resuspended in hybridization buffer 
(ULTRAhybTM, Ambion). After denaturation and re-annealing, hybridization on the array 
was performed in a GeneTAC Hybridization Station (Genomic Solutions. For post-
hybridization washing procedure Tween-20 (Merck) and SSC buffer as well as 
formamide (Applied Biosystems) was used. Finally, slides were dried by centrifugation 
(Heraeus) and scanned with an Agilent DNA Microarray Scanner Model G2505B (Agilent 
Technologies). For image analysis the GenePix Pro 6.1 software (Axon Instruments) was 
used. Data processing was carried out as previously described179,180. 
 
2.2.1.5 Methylation Array Processing 
Genome-wide DNA methylation was assessed using the Infinium HumanMethylation450 
BeadChip Kit (Illumina, San Diego, USA)181. Methylation analysis of medulloblastoma 
samples was performed according to the manufacturer’s instructions at the DKFZ 
Genomics and Proteomics Core Facility (Heidelberg, Germany).  
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2.2.2 RNA Procedures 
2.2.2.1 RNA Isolation 
For RNA extraction in order to perform microarray-based expression profiling, 1x107 cells 
were lysed in 1ml TRIZOL reagent (Invitrogen). After 5 min incubation at room 
temperature (RT) 300 μl chloroform was added, the sample was mixed thoroughly and 
incubated for 3 min at room temperature. Subsequently, a centrifugation step for 15 min 
at 4°C, 13.000 rpm followed. Thereafter, the aqueous phase was collected and mixed 
1:2 with 70% ethanol. The solution was applied to Micro RNeasy tubes (Qiagen) for 
further cleanup. After RNA binding to the column, a washing step with 350μl buffer RW1 
(supplied by the manufacturer) followed. Subsequently, a DNase digestion was 
conducted for 15 min at room temperature with 27U DNase per sample. Thereafter, the 
RNA was washed again with 350 μl RW1 buffer, 500 μl RPE buffer, and 500 μl 80% 
ethanol. Finally, the RNA was eluted in 15-30 μl RNase free water (Ambion) and stored 
at -80°C until further usage. 
 
For any other experiments, cells were lysed in 350 μl RLT buffer (Qiagen) and 
homogenized thoroughly. Subsequently, cell lysates were applied to RNeasy spin 
columns (Qiagen) and total RNA isolation was performed according to the 
manufacturer’s protocol (RNeasy Mini Kit, Qiagen). Elution from RNeasy spin columns 
was done with 2 x 30 μl RNase-free water (Ambion) following RNA precipitation for 1 h at 
-80 °C after adding 1 μ LPA (1 μg/μl), 30 μl ammonium acetate (7.5 M), and 225 μl 70 % 
ethanol. Finally, centrifugation for 30 minutes at 13.000 rpm, 4 °C and a washing step 
with 70 % ethanol followed. RNA samples were resolved in 20 μl RNase-free water. 
 
2.2.2.2 Quantification of Nucleic Acids 
Determination of DNA and RNA concentration in samples was performed via 
spectrophotometric measurement using a NanoDropTM ND-1000 spectrometer 
(Wilmington). Absorbance of samples was recorded at wavelength from 220 nm to 350 
nm and normalized to values of the corresponding pure solvent. Measurement at 260 nm 
(A260) was considered to detect DNA/RNA specific absorbance. In accordance with 
different coefficients for nucleic acid derivatives, an A260 value of 0.1 was equal to 50 
ng/μl double-stranded DNA, 40 ng/μl RNA or 33 ng/μl single stranded DNA, respectively. 
Besides quantification, the absorption spectra characteristics were evaluated for quality 
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determination of sample solutions regarding contaminations. Due to aromatic amino acid 
residues, proteins display a maximum absorbance at 280 nm (A280). Other commonly 
used substances like EDTA, phenol, and guanidine HCL show considerable absorbance 
at 230 nm (A230). Calculated ratios therefore indicate a clean solution of DNA and RNA 
for A260/A280 values of 1.8 and 2.0, respectively, and A260/A230 values between 2.0 
and 2.2. 
 
2.2.2.3 Assessment of RNA Quality 
Total RNA is rapidly degradated for biological as well as chemical reasons. In particular 
enzymatic digestion of mRNA by various types of RNases alters the transcript 
composition of samples nonstochastically. Thus, it is of particualr importance to assesss 
RNA integrity prior to sample preparation for whole transcriptome analyses and qRT-
PCR. Therefore, capillary gel electrophoresis on Agilent 2100 bioanalyzer was 
performed. In principle the RNA is stained with a dye and separated by size. According 
to the size distribution the RNA integrity number (RIN) is calculated based on values for 
18s and 28s rRNA fragments. For this procedure 300-500ng RNA were denatured for 2 
min at 70°C. The nano dye intercalating in RNA was mixed with the gelmatrix (both 
supplied by the manufacturer) and dispensed in the Nano Chip according to the 
manufacturer´s protocol. Subsequently, 1μl of denatured sample RNA as well as 1μl 
denatured ladder RNA were applied following RNA analysis by running the “Eukaryotic 
total RNA” program. Only samples with RINs > 8 were used for further analyses. 
 
2.2.2.4 Reverse Transcription 
For preparation of cDNA, 1 μg of total RNA from both tumor or cultured cells or 
Stratagene human reference RNA (Stratagene, La Jolla, USA) was used as a template 
for reverse transcription with SuperScript II Reverse Transcriptase Kit (Invitrogen, 
Karlsruhe, Germany) according to the manufacturer’s protocol. 
 
2.2.2.5 Design of Primer Pairs 
Forward and reverse primers for real-time PCR were designed manually following 
several aspects. The length of forward and reverse primer was between 20 to 30 base 
pairs and was designed to be similar in length if possible. The annealing temperature 
was calculated to be between 59 and 61°C. All primers were designed in an intron 
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spanning way to avoid amplification of genomic DNA. The possible generation of primer 
dimers and stem-loop structures was minimized by running the primer sequences on 
Oligonucleotide Property Calculator (http://www.basic.northwestern.edu/biotools/oligo-
calc.html). To guarantee gene specificity all primers were blasted on NCBI home page 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) and in-silico PCR using UCSC Genome Bio-
informatics platform (http://genome.ucsc.edu/). The primer pairs were purchased from 
Sigma-Aldrich. 
 
2.2.2.6 Quantitative Real-Time PCR (qRT-PCR) 
Quantitative real-time PCR is an established method to determine relative amounts of 
specific transcripts. It combines a RNA-dependent DNA synthesis, which is performed by 
a reverse transcriptase enzyme and is therefore termed reverse transcription (RT), with a 
subsequent PCR (polymerase chain reaction). The PCR on the initially generated cDNA 
uses specifically designed primers (see section 2.2.2.5) to only amplify the mRNA of a 
particular target gene and is conducted in the presence of the fluorochrome ABsolute-
QPCR SYBR® Green (ABgene). Upon intercalating into DNA double strands, this dye 
shows a more than 500-fold increase of light emission at 522 nm (λmax=522 nm). The 
measured fluorescence intensity at λmax therefore directly reflects the amount of 
amplified DNA and can be examined in real-time to monitor its exponential increase. The 
amount of transcript-specific DNA products at any reaction cycle is dependent on the 
initial mRNA abundance of the target gene and the primer efficiencies. The reaction 
consisted of 6 μl SYBR green, 0.12 μl forward primer (10 μM), 0.12 μl reverse primer 
(10 μM), 2 μl template cDNA (approximately 100 ng/μl) in a total volume of 12 µl. Each 
cDNA sample was analyzed in triplicates. Amplification and signal detection was done on 
an ABI PRISM 7900RT Sequence Detection System (Applied Biosystems). To calculate 
the efficiency of the PCR a standard curve for every amplicon was measured in every 
run with stratagene human reference RNA. Initially, the samples were denatured for 15s 
at 95°C followed by 40 cycles of 15sec at 95°C (denaturation),10sec at 60°C (primer 
annealing) and 72°C for 60sec. Data were analyzed using the SDS 2.2.2 software 
(Applied Biosystems). The relative quantification of the RNA of interest in comparison to 
two housekeeping genes (DCTN2, PGK1) was calculated according to a previously 
published algorithm182. 
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2.2.2.7 Microarray-based RNA Expression Profiling 
For the expression profiling experiments performed on transduced medulloblastoma cells 
containing pLKO.1 constructs, double-stranded cDNA was synthesized from extracted 
RNA via MMLV reverse transcriptase. Amplified fluorescent complimentary RNA (cRNA) 
was created via T7 RNA polymerase, which simultaneously amplifies target RNA and 
incorporates cyanine 3- or cyanine 5- labeled CTP with at least a 100-fold RNA 
amplification rate, and purified afterwards. cDNA synthesis, cRNA synthesis, 
amplification and labeling were done using the Agilent Quick Amp Labeling Kit. The 
labeled cRNA samples were then fragmented in fragmentation buffer at 60°C for 30 min 
before the microarray hybridization. cRNA of cells with SGK1 knockdown and cRNA of 
control cells transduced with nt shRNA were hybridized to a Whole Human Genome (4 × 
44K) Microarray (Agilent Technologies, Wilmington, DE, USA) overnight at 65°C in a 
Shel Lab hybridization oven (Sheldon Manufacturing, Cornelius, OR, USA). The 
hybridization slides were washed, stabilized, dried, and immediately scanned using the 
Agilent DNA Microarray Scanner. The acquired images were processed by the Agilent 
Feature Extraction Software. All steps were performed according to the Two-Color 
Microarray-Based Gene Expression (Quick Amp Labeling) Protocol (Publication Number: 
G4140-90050 v.5.7, Agilent Technologies, Wilmington, DE, USA). Result files containing 
all relevant raw data from the microarray-based RNA expression profiling experiments 
were processed using the in-house-developed ChipYard microarray analysis software 
(http://www.dkfz.de/genetics/ChipYard), and the statistical programming language R. 
 
2.2.3 Lentivirus-based Procedures 
2.2.3.1 Lentivirus-Mediated RNA interference (RNAi) 
Lentiviruses belong to the retrovirus family and are able to stably infect also non 
proliferating cells due to transferation of a pre-integrationcomlex following reverse 
transcription oft he RNA genome183. The lentiviral genome consists of regulatory genes 
(e.g. tat, rev) and accessory genes (vpu, vpr, vif, nef) contributing to efficient 
reproduction and pathogenesis, whereas three genes are essential for replication: gag 
(group-specific antigen), pol (polymerase), and env (envelope).  Gag encodes proteins 
fort he viral capsid, pol encodes viral enzymes such as protease, reverse transcriptase, 
and integrase. Env encodes membrane proteins for the viral envelope to adsorb the host 
cell. For producing infectious viral particles, essential genes are located on different 
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helper plasmids to ensure a safe gene transfer. The main vector contains genes for the 
integration into the host genome (5´ and 3´ LTR; long terminal repeats) and the 
packaging signal Ψ (psi). Instead the viral sequences between 5´ and 3´ LTR, an 
expression cassette coding for the transgene was included184. For silencing of the target 
gene SGK1, pLKO.1 constructs containing an expression cassette coding for a gene-
specific small hairpin RNA (shRNA) were used (Figure 9 A). Using the pLKO.1 lentiviral 
vector system (2nd generation), self-inactivating, recombinant lentiviruses (SIN viruses) 
were produced due to a deletion in the 3´ LTR region for inhibiting regulatory activities of 
both LTRs. The packaging plasmid psPAX2 (Addgene) encodes gag, pol, and rev. The 
second packaging plasmid pMD2.G (Addgene) encodes the glycoprotein G (vsv-G), 
thereby pseudotypical, recombinant viruses were produced targeting a wide spectrum of 
mammalian cells. After stable integration into the host genome, shRNAs were expressed 
and bind to the complementary endogenous SGK1 transcripts. The resulting dsRNA 
complexes lead to effective RNAi in the cell (45). This mechanism consists of processed 
RNA-duplexes by Dicer are integrated in RISC-complexes (RNA induced silencing 
complex). Thereby, the RNA strands were seperated by RISC and the antisense binds to 
complementary mRNA of the target gene followed by degradation of the heteroduplexes 
of mRNA and shRNA by enzymes of the RISC complex. 
 
2.2.3.2 Production of Lentiviral Particles 
Lentiviral particles were produced by co-transfection of HEK293T cells (passage <10) 
with the psPAX2, pMD2.G, and pLVX-Puro or pLKO.1 constructs (MISSIONTM TRC-Hs 
1.5)185 (Figure 9). 4x106 cells were seeded into 10cm cell culture plates in high glucose 
DMEM medium (Gibco) supplemented with 30% FCS (v/v), 1% penicillin/streptomycin 
(v/v) and 1% 200mM L-glutamin (v/v) and cultivated till reaching 70% confluency at 37°C 
and 5% CO2 in the incubator for 24h.  After exchanging medium (5ml), co-transfections 
were carried out using 2µg of each packaging plasmid and 4µg of pLVX-Puro or pLKO.1 
constructs, respectively. Therefore, 600µl OptiMEM medium with 30µl TransIT® 
Transfection Reagent (Mirus, Madison, USA) (5 mins incubation at room temperature) 
were mixed with the plasmids and incubated 20 mins at room temperature to allow 
forming transfection complexes. Subsequently, the mixture was dropped carfully onto the 
HEK293T cells, another medium exchange occured after 24h following viral production 
for another 24h (first harvest) and 48h (second harvest). Virus was harvested and 
concentrated at 48h and 72h after co-transfection. For increasing yields, upto three 
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plates were performed for each construct. Before virus concentration, GFP transfection 
efficiency was checked under the microscope. The transfected cells looked rounder and 
should be GFP positive. The medium slightly changed color, an indication of active cell 
metabolism. Using a 1ml pipette, the medium containing the lentiviruses was carefully 
collected from transfected plates without disturbing the HEK293T monolayer. Using a 
0.45 μm syringe filter (SFCA filter, Corning), medium was filtered into ultraclear SW41 
centrifuge tubes (Beckman). Filling each tube till 3-5mm from the top with liquid and 
balancing is important before ultracentrifugation using a SW41 rotor for 90 mins at 4°C at 
25.000 rpm. After centrifugation, the supernatant was carefully decanted into the waste 
bottle and virus pellet slightly dried. 100 μl sterile PBS or OptiMEM medium (Sigma) was 
added to the pellet and left standing covered at 4°C overnight. Finally, viruses were 
resuspended and 10µl stored as 10µl aliquots at -80°C. 
2.2.3.3 Determination of Virus Titer and Multiplicity of Infection (MOI) 
The effective titer of produced transduction units and the multiplicity of infection (MOI) 
was determined by transduction of HEK293T cells or medulloblastoma cells, respec-
tively. Therfore, lentiviral particles containing a GFP cDNA construct were carried with 
every virus production to measure titer and efficiency afterwards. Consecutive flow 
cytometry analysis was used for detection of GFP-positive cells. 
Calculation of virus titer: 
Titer [TU/µl] = (N*(P/100)*DF)*1/V  
TU: transduction units; N: cell number at transduction time point; P:percentage of GFP-
positive cells; DF: dilution factor; V: volume 
 
2.3 CELL	  BIOLOGY	  METHODS	  
2.3.1 Cell Culture Procedures 
2.3.1.1 Cell Culture 
All cell culture procedures were done under sterile conditions using a laminar flow 
workbench. The human medulloblastoma cell lines Daoy, MED8A, ONS-76, UW228-2, 
and UW228-3 were grown in Dulbecco's Modified Eagle Medium (DMEM; Invitrogen) 
supplemented with 10% fetal calf serum (FCS) and 1% penicillin/streptomycin (Gibco). 
D283 MED cells were grown in MEM alpha (Gibco) supplemented with 10% fetal calf 
serum (FCS) and 1% penicillin/streptomycin (Gibco). The normal culture conditions were 
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an adherent growth mode in poly-L-lysine-coated flasks (75 cm2, Nunc). All cell lines 
were grown in a humidified incubator at 37°C in 5% CO2/ 95% O2 and were routinely 
tested for authenticity and contamination186. For subculturing routineously every 3rd to 
4th day, cells were washed once with trypsin/EDTA (0.25%, 1 mM, Invitrogen) and then 
incubated again with trypsin/EDTA until detachment of cells occured. Following re-
suspension in DMEM and centrifugation, cells were resuspended in DMEM and seeded 
at ratios 1:5 to 1:15. For seeding of cells in appropriate densities cell number was 
determined using a Vi-CELL XR 2.03 cell counter (Beckman Coulter).  
 
Stock solutions of dexamethasone (Sigma-Aldrich) were prepared by dissolving the pure 
compound in 100% ethanol in order to achieve a primary concentration of 2.5 mM. The 
SGK1 antagonist GSK650394 was developed and kindly provided by GlaxoSmithKline 
(Oncology R&D; Collegeville, PA, USA) and stock solutions were prepared by dissolving 
the compound in DMSO at a concentration of 10 mM. Working dilutions were achieved 
by diluting the stock solutions directly in the appropriate cell culture medium. Prior to the 
administration of dexamethasone, all cells were grown for three days in medium 
containing charcoal-stripped FCS (Biochrom, Berlin, Germany). 
 
2.3.1.2 Cell Viability and Counting 
The viability and absolute number of cells were determined with a Vi-CELL XR 2.03 cell 
counter from Beckmann Coulter. Cells were automatically stained with trypan blue to 
exclude dead cells from the measurement and average number of cells per ml was 
calculated. 
 
2.3.1.3 Transduction of Medulloblastoma Cells 
Transduction was performed in either 6 well plates or 24 well plates, seeding 1x105 or 
5x104 cells, respectively. Following attachment and reaching 70-80% confluency after 
24h, stable transduction with recombinant, lentiviral particles containing a vector system 
with an expression cassette coding for either a gene-specific shRNA (pLKO.1) or SGK1-
HA transgene (pLVX-Puro) (see section 2.2.1.2) was conducted to induce SGK1 
knockdown or overexpression, respectively. Infections of medulloblastoma cells (Daoy, 
UW228-3) with an MOI of 10, were carried out in the presence of 8 μg/ml of polybrene 
and virus- containing supernatant was removed 20-24h post transduction. For gene 
silencing, five independent shRNA constructs targeting different regions of the SGK1 
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mRNA transcript were used (MISSION shRNA NM_005627; E7-11; Sigma-Aldrich, 
München, Germany). Non-targeting shRNA was used as a control. For overexpression of 
SGK1, pLVX-Puro vectors were used, and empty vectors were used as a control.  
Calculation of required virus volume: 
Virus volume [μl]=(N*MOI)/titer [TU/µl] 
N: cell number at transduction time point; MOI: multiplicity of infection; TU: transduction 
units 
 
To determine transduction efficencies, cells were transduced with GFP-containing 
viruses as a positive control for infection. Stable gene silencing was verified by qRT-PCR 
and Western blotting. Subsequently, diverse functional assays and analyses were 
performed using always freshly transduced medulloblastoma cells.  
 
2.3.2 Functional Analyses 
2.3.2.1 Viability and Proliferation Assay 
To assess the viability and growth rates of medulloblastoma cells in vitro under various 
treatment conditions, the MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl) 2Htetrazolium] based CellTiter 96 AQueous Non-Radioactive Cell 
Proliferation Assay (Promega, Madison, WI, USA) was used following the manufacturer´s 
recommendations (100µl medium + 20µl MTS/PMS, incubation 3h or 4h at 37°C in a 5% 
CO2 humidified incubator. MTS supplemented with phenazine methosulfate (PMS) is 
converted by metabolically active cells into a water-soluble formazan product with the 
absorbance quantity at 490nm which is detecable by ELISA-reader. The absorbance at 
490nm is proportional to the number of living cells in the test volume187. All samples were 
assayed in three or six technical replicates and experiments were performed at least 
twice. The half maximal effective concentration(EC50) of GSK650394, 4-HC and CCNU 
was calculated for each cell line separately using the GraphPad Prism 5.0 software 
(GraphPad Software, La Jolla, USA). 
 
2.3.2.2 Chemotherapy Experiments 
CCNU (lomustine) and cyclophosphamide are alkylating agents used in cancer 
chemotherapy. Clinical applied as a prodrug, cyclophosphamide is metabolized in vivo 
by cytochrome P450 enzymes mostly in the liver188,189 to generate 4-hydroxycyclo-
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phosphamide and its tautomer aldophosphamid which further dissociates into acrolein 
and the actually active phosphoramide mustard190-192. Therefore, in vitro experiments 
were conducted by use of an already activated form of cyclophosphamide, namely 4-
hydroperoxycyclophosphamide (4-HC) which is converted into 4-hydroxycyclophospha-
mide without enzymatic involvement193,194. 
 
Medulloblastoma cell suspension was diluted to 4x104 cells/ml, 4000 Daoy and UW228-3 
cells were seeded in 96 well microtiter plates in a volume of 100 μl and were allowed to 
attach for 24h. 4-HC (Niomech, Bielefeld, Germany) and CCNU (Medac, Wedel, 
Germany) purchased as powder, were dissolved immediate before application in ddH2O 
and absolute ethanol, respectively and diluted with the respective solvent and medium to 
the designated concentrations. Chemotherapeutics were applied at final concentrations 
ranging from 0.5μM to 40μM for 4-HC and from 5μM to 200μM for CCNU and cells were 
incubated for another 48h at 37°C in a 5% CO2 humidified incubator. At the designated 
timepoint MTS assay was performed according to section 2.3.2.1. using an incubation 
time of 4h. 
 
2.3.2.3 Irradiation Experiments 
Transduced medulloblastoma cells grown in either 96 well-plates for MTS assay or 24 
well-plates for apoptosis assay were exposed to ionizing radiation (IR) under using a 
Caesium-137 source of radiation at a dose rate of 0.512 Gy/min. IR doses ranging from 
2-10 Gy were determined to show significant effects on cell viability after 48 to 120h. As  
negative control (0 Gy), transduced cells were carried to the radiation source but finally 
not put into the irradiation chamber. 
 
2.3.2.4 Flow Cytometry 
Fluorescence activated cell sorting (FACS) is a method for separating microscopic 
particles like cells in a stream of fluid and passing them by a detection apparatus to 
determine individual features. FACS examines optical characteristics of cells, for 
example indicating size (forward scatter; FSC) or granularity (side scatter; SSC) 
detectable as light scattering. In particular, measurement of fluorescence intensities 
enables this technique to quantify any labeled component of an individual cell and hence 
to compile various distributions of cellular features within a given population. Flow 
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cytometry analyses reported in this study were performed on a FACSCanto II flow 
cytometer (BD Bioscience) using BD FACS Diva software (BD Bioscience). 
 
2.3.2.5 Cell Cycle Analysis and Detection of SubG1-fractions 
Cell cycle analyses are generally distinguished from proliferation assays as they provide 
a snapshot of the cell cycle with quantitative information about cell proportions residing in 
different phases. Propidium iodide (PI) is a DNA-intercalating substance being quanti-
tatively detectable by fluorescence measurements. Accordingly, using FACS analysis, 
stained cells can be discriminated between a normal diploid karyotype, representing G0 
or G1-phase, and a tetraploid karyotype, indicating G2-phase or mitosis. Apoptotic cells 
are characterized by a hypoploid DNA content and discriminable from cells with normal 
(diploid) DNA content, thus represented as subG1-fraction. Besides the two distinct 
distribution peaks of G0/G1 and G2/M, a transient intermediate state can be identified 
representing S-phase. The relative amount of cells being in G0/G1 or G2/M at the time 
point of preparation can reflect overall difference in proliferation behavior or distinct 
imbalances in checkpoint control and thus provides a suitable overview of the cell cycle. 
For detection of cell cycle phases after medulloblastoma cell treatment, Nicoletti assay 
was performed195. Transduced medulloblastoma cells were stained with PI by incubation 
in hypotonic buffer containing 50μg/ml PI (Propidium iodide, Sigma Aldrich, Munich, 
Germany), 0.1% sodium citrate and 0.1% Triton X-100 (Sigma Aldrich, Munich, 
Germany) for 4h at 4°C in the dark. Nicoletti buffer was applied 1:1 (v/v) directly into the 
well where cells are grown. Due to the hypotonic propensity of the buffer, cell nuclei were 
extracted and subjected to FACS measurement using FACSCanto II (BD Biosciences). 
For each measurement, at least 20.000 events were counted. Nuclei fluorescence after 
laser excitation was used to quantify the distribution of cells in each cell-cycle phase: 
subG1, G1, S and G2/M. Analysis was evaluated using FACSDiva software (BD 
Biosciences). 
 
2.3.2.6 Apoptosis Assay 
Phosphatidylserine externalization as a measurement for early apoptosis was analyzed 
by flow cytometry. To quantify apoptotic cells, double stainings with Annexin V-PE and 7-
amino-actinomycin (7-AAD) were conducted. Therfore, 1x105 to 1x106 transduced or 
drug treated medulloblastoma cells were harvested by centrifugation. Subsequently, cells 
were incubated with 30μl of an Annexin V-PE/7AAD solution (1:10 Annexin V-PE/7AAD 
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in 1x annexin binding buffer) for 15min at 4°C in the dark. Directly after incubation 150μl 
of 1x annexin binding buffer was added, immediately followed by flow cytometry using 
FACS Canto II (BD Biosciences). For each measurement, at least 10.000 events were 
counted. Data were analyzed using the FACS Diva software (BD Biosciences). 
 
2.3.2.7 Migration Assay 
An well-established method to determine differential numbers of migrated cells under 
various conditions is provided by the Boyden chamber assay. The assembly comprises 
an upper compartment where the cells are seeded in cell culture medium, and a lower 
compartment containing culture medium supplemented with a diffusible migration 
stimulus. Both compartments are separated through a porous membrane allowing the 
stimulus to spread and attract cells to actively pass. The pores size approximately 
constitutes half the cell diameter and therefore favors an active movement towards the 
increasing attractant gradient over a sporadic motility. The relative amount of cells 
residing in the lower compartment, after incubation in the presence of an adequate 
stimulus, gives an indication of different migration properties. In the present study, a 
migration assay using 24-well plates with transwell inserts (8 μm pores, BD Falcon) was 
applied to adherent medulloblastoma cells (Daoy, UW228-3) transduced with pLVX-
SGK1-HA or pLVX-empty vector constructs, respectively. 50.000 cells were seeded into 
the inserts (upper compartment) containing medium with 0.5% serum, whereas the lower 
compartment contained medium with 10% serum as a migration stimulus. Cells were 
allowed to migrate 24h at 37°C and 5% CO2. Subsequently, transwell inserts were taken 
off and cells at the membrane, facing the upper compartment, were thoroughly removed 
with a cotton wool stick. Cells at the bottom of the membrane were washed with PBS and 
fixated for 15 minutes in 5% PFA. Afterwards, membranes with fixated cells were rinsed 
with PBS and the membrane was cuttet out from the well. Thereafter, the membrane was 
mounted on glass slides using ProLong® Gold mounting medium containing DAPI 
nuclear stain (Invitrogen, Karlsruhe, Germany). Finally, stained nuclei were counted at 
the microscope. 
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2.4 PROTEIN	  BIOCHEMISTRY	  METHODS	  
2.4.1 Protein Procedures 
2.4.1.1 Isolation of Protein 
For extraction of total protein of cultured cells, 1x106 medulloblastoma cells were pelleted 
by centrifugation and washed with PBS prior to addition of 40-70µl RIPA-lysis buffer. 
RIPA buffer (Sigma-Aldrich) was supplemented with 10 mM NaF, 1 mM sodium 
orthovanadate, 10 mM phenylmethylsulfonylfluorid (PMSF), and complete Mini Protease 
Inhibitor Cocktail Tablets (Roche) for Ser/Thr phosphatase and protease inhibition.  
 
2.4.1.2 Protein Concentration Measurement by BCA Assay 
Protein was quantified using a colorimetric assay based on reduction of Cu2+ by peptide 
bonds to Cu+ ions under alkaline conditions, which is then chelated by bicinchoninic acid 
(BCA) and exhibit a high absorbance at 562 nm. Thus, 40 µl 0.1% copper-II-sulfate in 
BCA was added to 2 µl of protein solution and incubated for 30 min at 37°C. Absorption 
was measured and protein concentration was derived from a standard series generated 
with bovine serum albumine (BSA). 
 
2.4.1.3 Western Blot Analysis 
Size-dependent, electrophoretic separation of protein fractions were performed with 
SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis). Therefore, gels 
of 1 mm thickness were prepared using the Mini-PROTEAN system (BioRad) by 
successively casting separation (10 % acrylamide, 375 mM Tris, pH 8.8, 1% SDS, 0.1% 
APS (ammoniumpersulfate) and 0.01% TEMED (N,N,N’,N’-tetramethylethylenediamine)) 
and stacking gel (5% acrylamide, 125 mM Tris, pH 6.8, 0.1% SDS, 0.1% APS and 0.01% 
TEMED). Alternatively, gradient gels (Lonza PAGEr* Gold Precast Gels, LONZA) were 
used together with Tris-Glycine SDS running buffer (25 mM Tris, 192 mM Glycine, 0.1% 
SDS, pH 8.3. Protein extracts were adjusted to the maximum equal concentration. For 
gel loading 5 x Laemmli buffer (8% SDS, 200 mM Tris, pH 6.8, 0.08% bromphenol blue, 
40% glycerol, 10% 2-mercaptoethanol) was added to 40µg total protein and denatured 
for 5 min at 95°C. For size estimation, Spectra multicolor broad range ladder 
(Fermentas) was loaded on the gel together with protein samples. SDS-polyacrylamide 
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gel electrophoresis (SDS-PAGE) was performed in SDS running buffer with an initial step 
of 5 min at 65 V following 60-80 min at 130 V. Transfer onto a polyvinyliden flouride 
(PVDF) membrane was performed in a tank blotting procedure using a Mini Trans-
Blotwet gel transfer system (Biorad) and a transfer buffer composed of 25 mM Tris, pH 
8.8, 200 mM glycine, and 20 % methanol with stepwise increasing current (10 min 
100 mA, 10 min 200 mA, 10 min 300 mA, 10 min 400 mA and 20 min 500 mA). The 
whole blotting procedure was carried out under permanent ice cooling to prevent heating 
of the buffer due to high currents. After completed transfer membrane was washed 
briefly in TBS-T (150 mM NaCl, 10 mM Tris, and 0.1% Tween-20, pH 7.4) and blocked in 
10% milk/3%BSA in TBS-T for 1 h at room temperature. Protein detection was done 
using antibodies in the recommended dilutions, given in section X in 1:10 blocking 
solution at 4°C over night. After washing 3 x 5 min in TBS-T and incubation with horse-
radish peroxidase (HRP) coupled secondary antibodies for 1 h at room temperature, the 
membrane was washed and subjected to chemiluminescent detection using ECL or 
ECLplus (GE Healthcare). X-ray films (FUJI) were exposed to stained blots in a 
developing cassette (exposure time individually adjusted).  For subsequent detection of 
different epitopes on the membrane, bound antibodies were removed by incubation at 
52°C in stripping buffer (6.25 mM Tris pH 6.5, 2% SDS, 0.8% ß-mercaptoethanol) for 
30 min followed by 1 h blocking. 
 
2.4.2 Immunostaining Prodedure 
2.4.2.1 Immunohistochemistry (IHC) 
A custom tissue microarray (TMA) of pediatric medulloblastoma samples was 
constructed for investigation by immunohistochemistry. Hematoxylin and eosin (HE)-
stained sections from all paraffin blocks were prepared to identify representative tumor 
regions as previously described196. In addition, samples of non-neoplastic cerebellar 
tissues were prepared as a control. Immunohistochemistry was performed based on an 
indirect streptavidin-biotin method. 10 μm sections of the recipient block were prepared, 
deparaffinized and epitopes were retrieved by immersion of tissue sections in pre-heated 
10 mM citrate buffer (pH 6.0) and maintained heating in a microwave oven for 10 min. 
Endogenous peroxidase activity was inhibited by 3% hydrogen peroxide. Primary anti-
human antibody against SGK1 (Abcam, Cambridge, UK) was used. Biotinylated anti-
rabbit immunoglobulin served as secondary antibody. Sections were incubated with 
horseradish peroxidase-conjugated streptavidin for 15 min to increase the sensitivity of 
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the detection system. For color development, the specimens were incubated with 3,3'-
diaminobenzidine hydrochloride (DAB) supplemented with hydrogen peroxide and 
afterwards counterstained in hematoxylin. Antibody diluent, secondary antibodies and 
detection system were used according to the manufacturer’s instructions (Dako, 
Glostrup, Denmark). Scoring of antibody staining cytoplasmic and nuclear immuno-
reactivity were scored separately according to staining intensity and graded semi-
quantitatively by neuropathologists. For statistical analyses, the immunostaining classifi-
cations were reduced to two categories: low and high expression of the evaluated 
antigens of interest. Estimation of survival time distributions was performed by use of the 
Kaplan-Meier analysis. For comparisons of survival curves, the log rank test was used 
and univariable Cox proportional hazards regression models were applied to examine 
the association of molecular markers with the hazard of death from disease and disease 
progression. To account for multiple testing, p-value adjustment was calculated. 
 
2.5 STATISTICAL	  ANALYSES	  
Kaplan-Meier survival curves were compared by the Cox-Mantel log-rank test in Winstat 
for Excel (R. Fitch Software, Germany). P-values were calculated with a two-tailed 
student´s t-test and ANOVA (analysis of variance) was performed using Microsoft Excel 
or GraphPad Prism 5.0 software, respectively. 
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3 RESULTS	  
3.1 IDENTIFICATION	  OF	  SGK1	  AS	  CANDIDATE	  GENE	  IN	  MEDULLOBLASTOMA	  
Previous studies based on DNA copy-number aberrations demonstrated that chromo-
some 6q status defines subgroups of medulloblastoma patients with distinct clinical 
outcome111. Array-CGH analysis demonstrated balanced 6q copy-number status in 44 of 
the 64 investigated medulloblastoma samples (69%). A chromosomal gain of 6q was 
shown in 5 tumors (8%). 15 medulloblastomas (23%) exhibited loss of chromosome arm 
6q. In order to identify potential candidate genes located on chromosome arm 6q, which 
are affected by respective changes in gene expression, microarray-based transcriptome 
analysis was performed. To identify genes differentially expressed between the different 
subgroups, pooled RNA of five medulloblastoma samples carrying 6q gains were co-
hybridized with pooled RNA of five medulloblastoma samples showing a monosomy of 
chromosome 6. The top 50 upregulated genes at chromosome 6q obtained from this 
approach are listed in Supplementary Table 1 (Appendix). 
 
3.1.1 SGK1 mRNA Expression is correlated with Chromosome 6q 
Copy-Number Status in Medulloblastoma 
In an attempt to further investigate the interrelation between gene expression and 6q 
copy-number status, transcriptome analysis was performed for each of the tumor 
samples investigated by array-CGH. This analysis revealed several interesting 
candidates after ranking the most differentially expressed genes according to their 
differences comparing the mean values of medulloblastoma harboring a 6q gain vs. 
tumors with 6q loss. The complete gene list of the top 50 candidates is shown in 
Supplementary Table 2 (Appendix). Interestingly, SGK1, one of the top-ranking genes 
among the identified candidates to be upregulated in medulloblastomas possessing 6q 
gain, was also among the top-ranking genes in the initial expression profiling experiment 
described above. The respective clones on the microarrays represented the transcription 
start site of serum- and glucocorticoid regulated kinase (SGK1) at chromosome locus 
6q23.2. This gene encodes a serine/threonine protein kinase that plays an important role 
in cellular stress response and is a crucial member of frequently deregulated pathways in 
medulloblastoma. For medulloblastoma samples for which a sufficient amount of RNA 
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material was available (n=41), the results derived from the expression profiling 
experiment Figure 10, left panel) were validated by quantitative real-time PCR (QRT-
PCR) (Figure 10, right panel). A high correlation of SGK1 mRNA expression levels with 
copy-number status of chromosome arm 6q was shown. The positive correlation was 
stronger than an expected gene-dosage effect (mean log2-ratio of 2.22 in tumors with 6q 
gain vs. mean log2-ratio of -2.79 in tumors exhibiting 6q loss when compared to normal 
cerebellum; p < 0.0001), suggesting a functional role of this kinase in tumor biology of 
the different subgroups. 
 
 
Figure 10 Expression levels of SGK1 mRNA in primary medulloblastoma. SGK1 expression values of 
64 medulloblastoma samples derived from microarray transcriptome analysis were grouped according to 
chromosome arm 6q copy number status (left panel). These results were validated in a subset (n=41) of 
tumors from which sufficient amounts of RNA were was available, using quantitative real-time PCR (right 
panel). SGK1 mRNA expression levels are shown as log2-ratios when compared to normal cerebellum (pool 
of non-neoplastic cerebellar tissue from 24 male/female Caucasians). Statistical significance was assessed 
using unpaired t-tests. The experimental analyses were performed by Prof. S. Pfister et al. in collaboration 
with D. Sturm, DKFZ, Heidelberg). 
 
3.1.2 SGK1 is Differentially Expressed Between Medulloblastoma 
Molecular Subgroups 
In order to investigate SGK1 mRNA expression levels according to molecular consensus 
subgroups as suggested by Taylor et al.83, our data set (n=64) was enlarged (n=152) 
and combined with recently published medulloblastoma transcriptome studies by Kool et 
al.85 (n=61), Fattet et al.197 (n=55), and McCabe et al. (unpublished) (n=34) to a total 
number of 302 medulloblastoma samples, accessible via the microarray analysis and 
visualization platform ‘R2’. Annotation with genetic aberrations and clinical factors 
demonstrated monosomy 6 being exclusively present in WNT-driven medulloblastomas 
and 6q gain was restricted to Non-WNT/Non-SHH tumors. Expression levels of SGK1 
mRNA were distinct in subgroups, displaying high expression in variants with molecular 
  
	   Results 	  	   	  
57 
and clinical high-risk factors (Group 3 and 4), whereas low expression was detected in 
cases with excellent and intermediate prognosis (WNT and SHH, respectively, Figure 11 
A). This subgroup-specific expression patterns revealed that high SGK1 expression 
levels were largely limited to Group 3 and 4, thus indicating that it constitutes an 
excellent marker gene for non-WNT/non-SHH medulloblastoma. 
 
3.1.3 SGK1 Protein Expression is correlated with Overall Survival of 
Medulloblastoma Patients 
Furthermore, protein levels of SGK1 were evaluated in an independent cohort of 260 
medulloblastoma samples represented on a tissue microarray (TMA) using immuno-
histochemistry (IHC). SGK1 positivity was detected in 26% of samples, whereas the 
remaining 74% of the tumors disclosed a negative or weakly positive immunostaining. 
Survival analysis by Kaplan-Meier analysis revealed a significant association of SGK1 
immunopositivity with poor overall survival (p = 0.0168, Figure 11 B), indicating SGK1 as 
a potential prognostic marker for high-risk medulloblastoma. 
 
 
Figure 11 A) Subgroup-specific gene expression patterns of SGK1 in medulloblastoma. mRNA 
expression profiles were accessible via the microarray analysis and visualization platform ’R2’. Untrans-
formed, non-normalized SGK1 gene expression values of medulloblastoma samples (n=302), initially 
generated on Affymetrix gene expression arrays from different data sets were combined. Statistical 
significance was calculated using one-way ANOVA (p<0.0001). B) Survival analysis of medulloblastoma 
patients according to SGK1 immunohistochemistry. Overall survival probabilities for negative or strong 
(mainly nuclear) staining in medulloblastoma (n=217) were estimated from the the time point of diagnosis 
using Kaplan-Meier analysis. Medulloblastoma patients with high SGK1 protein expressing tumors showed a 
significant association with poor survival. The p-value of the analysis is given (p=0.0168). This experiment 
was performed by Prof. S. Pfister et al. in collaboration with Dr. M. Remke; the evaluation by Prof. A. 
Korshunov, DKFZ, Heidelberg. 
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3.1.4 SGK1 is Differentially Methylated Across Medulloblastoma 
Subgroups 
To further investigate alternative mechanisms explaining subgroup-specific SGK1 
expression patterns beyond a gene-dosage effect, PCR based analyses were performed 
in order to detect the abundance of an evolutionarily conserved N-terminal SGK1 mRNA 
variant with enhanced stability and improved function. This alternate transcript of SGK1 
encodes an isoform, which has been described to be more stable, less susceptible to 
ubiquitinylation and which was observed to possess improved physiological propensity of 
epithelial ion channel conductance compared to other SGK1 isoforms141. However, 
upregulation of this specific transcript did not seem to play an essential role in elevating 
SGK1 activity, as the relative expression in our cohort was negligible comparing it to the 
overall expression of other SGK1 transcripts (data not shown). In tumors with 6q loss, 
the alternative transcript could be marginally detected and no significant differences were 
observed between tumors with 6q gain or balanced 6q. 
A complementary approach was taken by screening for activating mutations in SGK1, 
which could provide an alternative mechanism of abnormal SGK1 regulation by creating 
a constitutively active form. For this purpose, all exons of  SGK1 were investigated by 
genomic sequencing of 25 medulloblastoma samples and corresponding germline DNA 
of these patients. This analysis revealed no mutations in SGK1 comparing medullo-
blastoma vs. matched germline samples. 
 
To account for epigenetic regulatory events governing SGK1 mRNA expression, a bisul-
fite conversion-based analysis of medulloblastoma samples (n=115) was conducted 
using the Human Methylation 450K Array from Illumina. This method allowed monitoring 
of more than 485.000 potential methylation sites per sample at single-nucleotide reso-
lution. Also CpG sites outside of CpG islands and coding regions were covered by this 
approach. While 5’promoter methylation was virtually absent across all medulloblastoma 
samples, focusing on the methylation status of CpG sites in the SGK1 locus (gene body 
and 3’UTR) revealed clear subgroup-specific differences. Significantly higher methylation 
was found in the WNT and SHH-subgroups, whereas almost no gene body methylation 
was observed in Group 3 and Group 4 tumors, as shown in Figure 12. The result shows 
a highly significant negative correlation of SGK1 mRNA expression levels and extent of 
methylation of  several CpG sites clustering together in the 3’ end of the SGK1 gene  
(R=-0.8).  
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Figure 12 Subgroup-specific DNA methylation patterns of SGK1 across medulloblastoma 
subgroups. Bisulfite conversion-based analysis of medulloblastoma samples (n=115) was performed using 
the Human Methylation 450K Array from Illumina. Methylation status of CpG sites in a 152 kb large region 
representing the SGK1 gene located on chromosome 6 (q23.2) is depicted. Tumors of the WNT and SHH-
subgroup showed significantly more methylated (red) CpG sites of gene body and 3’UTR than tumors of 
Group 3 and Group 4 (R=-0.8). Unmethylated CpG sites are shown in blue. This experiment was performed 
by Prof. S. Pfister et al. in collaboration with Dr. D. Jones & Dr. M. Kool, DKFZ, Heidelberg. 
 
3.1.5 Medulloblastoma Cell Lines Exhibit Different Variable SGK1 
Expression Levels and Inducibility by Glucocorticoid Treatment 
In order to find an adequate cell culture model system for studying the biological role of 
SGK1 in medulloblastoma pathogenesis, various established medulloblastoma cell lines 
were investigated initially for endogenous SGK1 expression levels and inducibility. SGK1 
mRNA levels were determined relative to the mean of two housekeeping genes (DCTN2, 
PGK1) in estabished cell lines DAOY, MED8A, ONS-76, D283 MED, UW228-2 and 
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UW228-3 using QRT-PCR. Under basal conditions, SGK1 mRNA was overexpressed 
compared to normal cerebellum in DAOY and UW228 cell lines, whereas lower 
expression was found in MED8A, ONS-76, and D283 MED cell lines (Figure 13 A). The 
highest expression levels were observed in UW228 cell lines, likely due to gene-dosage 
effects caused by a focal high-level amplification at chromosome 6q23.2, harboring the 
SGK1 gene as assessed by array-CGH (data not shown). Furthermore, assessment of 
SGK1 abundance in these cell lines was also conducted on protein levels using Western 
blot analysis. To determine whether SGK1 is inducible on transcription level by 
administration of glucocorticoids using dexamethasone (DEX, 1 μM), cells were treated 
with DEX for 24h or left untreated (vehicle control). DEX was previously described to 
induce SGK1 expression on transcriptional levels via activation of the glucocorticoid 
receptor (GR)130. The upregulation of SGK1 mRNA levels in the presence of 
glucocorticoids (data not shown) was accompanied by a large increase of SGK1 protein 
levels in DAOY, ONS-76 and UW228 cell lines after 24h exposure to DEX, whereas no 
induction was observed in MED8A, and D283 MED cells (Figure 13 B). The endogenous 
SGK1 protein levels were also depicted and matched proportionately to the obtained 
mRNA expression levels shown in Figure 13 A. Taken together, these studies confirmed 
SGK1 being a downstream target of the glucocorticoid receptor in medulloblastoma cells. 
 
 
 
Figure 13 A) Endogenous mRNA levels of SGK1 in various medulloblastoma cell lines. Expression 
values were given relative to the mean of two housekeeping genes (DCTN2, PGK1) and compared to normal 
cerebellum as measured by quantitative  real-time PCR. B) Dexamethasone treatment of medullo-
blastoma cell lines induces SGK1 protein expression. Upregulation of SGK1 protein levels in various 
medulloblastoma cell lines was detected by Western Blot analysis with or without dexamethasone (DEX, 1 
μM) treatment for 24 h. Control cells were equally treated with vehicle only. SGK1 protein levels were 
strongly upregulated upon dexamethasone treatment in DAOY, ONS-76, and UW228 cells, whereas no 
induction was observed in MED8A, and D283 MED cells. These experiments were performed by D. Sturm, 
DKFZ, Heidelberg. 
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3.2 FUNCTIONAL	  ANALYSES	  AFTER	  MODULATING	  SGK1	  IN	  
MEDULLOBLATOMA	  CELL	  LINES	  
To get a better understanding of the functional role of SGK1 in medulloblastoma patho-
genesis and course of disease, phenotypic assays were performed after modulating 
SGK1 expression in vitro. Since Daoy and UW228-3 medulloblastoma cell lines showed 
basic SGK1 expression levels detectable by QRT-PCR and Western blot analyses and 
moreover turned out to be inducible by dexamethasone, they were regarded as suitable 
cell culture models. Firstly, C-terminally HA-tagged SGK1 cDNA was cloned into a 
lentivirus compatible pLVX-vector to estabish stable SGK1 overexpression in cell lines. 
For lentivirus-mediated knockdown of SGK1, a commercially available set of shRNAs 
(short hairpin RNAs) targeting SGK1 and respective non- targeting shRNA (nt shRNA) 
control plasmids (pLKO.1 vector backbone) from Sigma were used. After producing 
infectious lentiviral particles containing either the SGK1 construct, or empty-vector / nt 
shRNA control particles, the (multiplicity of infection) MOI was calculated for each cell 
line. For both cell lines, an MOI of 5 was calculated, but satisfying phenotypic effects of 
SGK1 modulation were only seen with a transduction efficiency >90% using an MOI of 
10. Therefore, this was maintained for all further experiments described below. 
 
3.3 PHENOTYPIC	  ASSAYS	  AFTER	  STABLE	  OVEREXPRESSION	  OF	  SGK1	  IN	  
MEDULLOBLASTOMA	  CELL	  LINES	  
A series of lentivirus-mediated overexpression experiments was performed to increase 
SGK1 expression levels. The readout included expression measurement of SGK1 on 
prorein level using Western blot analysis to confirm elevated SGK1 levels prior to investi-
gation of resulting phenotype. Subsequently, assays evaluating proliferation, apoptosis 
and migration were conducted. 
 
3.3.1 SGK1 Overexpression has no Effect on Proliferation 
For the purpose of demonstrating SGK1 specific effects on cell viability and growth rates, 
MTS assays were performed starting three days post transduction of Daoy and UW228-3 
cell lines with lentiviruses containing the pLVX-constructs. After seeding the same 
numbers of SGK1-overexpressing cells and respective empty-vector control cells into 96-
well plates, the readout was performed every 24h for a time series of five days. The cell 
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viability was commensurated to the absorbance at 490nm. In both cell lines, Daoy and 
UW228-3, cells overexpressing SGK1 compared to control cells consistently did not 
significantly alter viability or growth characteristics (Figure 14). 
 
 
Figure 14 Determination of cell viability and growth rates upon SGK1 overexpression. Depicted is the 
absorbance at 490nm representing the metabolic activity of Daoy (left panel) and UW228-3 (right panel) 
medulloblastoma cells using MTS-assay. Three days post transduction with respective pLVX-constructs 
MTS assays were performed every 24h for a total of five days. Cells overexressing SGK1 are shown as 
continuous lines, empty vector controls as dotted lines. The values are means ± SD of six technical 
replicates. 
 
3.3.2 SGK1 Overexpression leads to Increased Migration Rates 
As a next step, the influence of SGK1 on medulloblastoma cell migration was 
investigated. Consequently, Daoy and UW228-3 cells were transduced with pLVX-SGK1-
HA containing viruses or empty vector control viruses, respectively. Transduction 
occured four days prior to executing transwell assays by the usage of Boyden chambers 
filled with media containing 0.5% fetal bovine serum (FBS) in the upper compartment. 
Migration was directed towards a serum gradient achieved by a membrane with 8μm 
pore size separating the lower compartiment filled with media containing 10% FBS as 
attractant. Increase of migration propensity of cells harboring respective pLVX-constructs 
correlated exactly with their SGK1 protein expression levels (Figure 15 A, C, D). In 
parallel, MTS assays were performed to ensure equal viability and growth rates of the 
investigated medulloblastoma cells. As expected, no difference was seen in cell viability 
(Figure 15 B), whereas cells with elevated SGK1 protein levels showed a significant 
increase in migration rates up to 3-fold for Daoy and 2-fold for UW228-3 cells. 
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Figure 15 Migration rates of medulloblastoma cells with or without overexpression of SGK1. Cells 
were either transduced with pLVX-SGK1-HA containing lentiviral particle or pLVX-empty vector control 
viruses (MOI 10) four days prior to the transwell assay. A) Five days post transduction, SGK1 protein 
expression levels in Daoy and UW228-3 cells were detected by Western Blot analysis. B) MTS assays of 
Daoy and UW228-3 cells were performed in parallel to the migration assay to ensure equal viability and 
growth rates of the cells. C) and D) Migration of transduced Daoy and UW228-3 cells occured from media 
containing 0.5% FBS in the upper compartment towards media with 10% FBS in the lower compartment 
using a 24-well format Boyden chamber with 8µm pore size. Increased migration rates of cells harboring 
respective pLVX-constructs correlated strongly with their SGK1 protein expression levels. The values are 
means ± SD of six technical replicates and normalized to empty vector control cells (p < 0.0001), 
respectively. These experiments were performed in collaboration with Prof. F. Lang et al. and Dr. Eva-Maria 
Schmidt, Institute of Physiology, Tübingen. 
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3.3.3 SGK1 Overexpression has no Effect on Irradiation - but on 
Chemotherapy Resistance 
Current multimodal treatment protocols for standard- and high-risk medulloblastoma 
patients include surgical resection, different intensities of craniospinal gamma irradiation 
(17-36 Gy to the neuroaxis, 50-55 Gy to the posterior fossa), and varying regimens of 
chemotherapy101,102. As SGK1 was described to exhibit anti-apoptotic properties and to 
promote cell survival in several solid tumors125,171, the following approach was used to 
elucidate whether SGK1 protects against irradiation-induced cell death in medullo-
blastoma: Daoy and UW228-3 cells were transduced with lentiviruses containing pLVX-
constructs three days prior to irradiation at different doses. Viability and growth rates of 
medulloblastoma cells with or without overexpressing SGK1 were monitored up to three 
or five days, respectively, by using MTS assays. No differences of cells overexpressing 
SGK1 compared to control cells regarding radiation sensitivity were obtained with this 
experimental setup (Figure 16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16 Viability and growth rates of medulloblastoma cells with or without overexpressing SGK1 
exposed to irradiation at the indicated doses. Depicted is the absorbance at 490nm representing the 
metabolic activity of Daoy (left panel) and UW228-3 (right panel) medulloblastoma cells using MTS-assay. 
Three days post transduction with respective pLVX-constructs, cells were exposed to irradiation at the doses 
indicated and MTS readout was performed every 24h for a total of three days (A) or five days (B), 
respectively. Cells overexpressing SGK1 are shown as continuous lines, empty vector controls as dotted 
lines. The values are means ± SD of six technical replicates. 
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To determine the role of SGK1 specifically in apoptosis-sensitivity towards radiotherapy, 
an additional experimental approach was choosen. Medulloblastoma cells were tested 
for the extent of apoptosis after irradiation with or without SGK1 overexpression by the 
usage of FACS-based Annexin V-PE/7AAD assay. This method exploits a property of 
most cells to translocate phosphatidylserine from the inner layer of the plasma 
membrane to the outer site, being detectable at the surface then. This exposure 
indicates the initial stages of apoptosis prior to morphological changes or loss of cellular 
integrity. Annexin V specifically binds to phosphatidylserine and can be used to measure 
apoptosis by covalently attaching a fluorochrome (e.g. phycoerythrin, PE). In order to 
identify late apoptotic or necrotic cells in addition, this measurement is complemented by 
the application of a DNA-intercalating fluorescent dye (7AAD, 7-aminoactinomycin), 
taking advantage of the disrupted membrane integrity in these cells. Daoy and UW228-3 
medulloblastoma cells were transduced with pLVX-SGK1-HA or empty vector and three 
days later irradiated with 3 Gy and 6 Gy, whereas the control cells kept unirradiated. 
After another four days apoptotic cell populations were determined (early and late 
apoptosis) and plotted as percentages as depicted in Figure 17. In addition, the ratios of 
means were normalized to empty vector controls at respective irradiation doses which is 
showed as numbers at the bottom. This experiment confirmed the results measured by 
MTS assay, as no significant alterations in apoptosis rates due to SGK1 upregulation 
were obtained in both cell lines. 
 
 
Figure 17 Determination of apoptosis rates in medulloblastoma cells with or without overexpressing 
SGK1 exposed to irradiation at the doses indicated. FACS-based apoptosis assay was performed on 
freshly harvested cells stained with Annexin V and 7-AAD detecting early and late apoptosis, respectively. 
Shown are percentages of apoptotic cell populations obtained from transduced Daoy (A) and UW228-3 (B) 
cells exposed to irradiation at different doses three days post transduction. Cells were either transduced with 
pLVX-SGK1-HA containing lentiviral particles or pLVX-empty vector control viruses (MOI 10) seven days 
prior to FACS analysis. The values are means ± SD of technical triplicates. The numbers at the bottom 
indicate ratios of means normalized to empty vector controls at different irradiation doses. 
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Notably, beside of protection from apoptosis, also increased chemotherapy resistance 
upon glucocorticoid treatment has recently been described in various solid cancers 
including brain tumors174,198. Therefore, in vitro experiments were perfomed treating 
medulloblastoma cell lines with the alkylating agents 4-hydroperoxycyclophosphamide 
(4-HC) and lomustine (CCNU), which play a role among others in chemotherapy regimen 
for medulloblastoma patients. Both chemotherapeutics induce DNA doublestrand breaks 
(DSB). To evaluate the half-maximal effective concentration (EC50) of the substances 
after 48h in medulloblastoma cell lines, the effect of various concentrations applied on 
Daoy and UW228-3 wildtype cells was investigated by use of MTS assays. For 4-HC 
doses ranging from 0.5 μM to 40 μM and for CCNU doses ranging from 5 μM to 200 μM 
were tested. A significant reduction of tumor cell viability was observed in both cell lines 
in a dose-dependent manner. Dose response curves after 48h and EC50 values per cell 
line were indicated in Figure 18. UW228-3 cells turned out to be less sensitive for 
treatment than Daoy cells. 
 
 
Figure 18 Dose response curves to determine the EC50 of 4-HC and CCNU after 48h exposure to 
medulloblastoma cell lines. The relative metabolic activity of Daoy (blue) and UW228-3 (red) 
medulloblastoma cells after 48h exposure to varying concentrations of 4-HC or CCNU as indicated, is shown 
using MTS-assay. The values are means ± SD of technical triplicates and plotted relative to control cells 
treated with vehicle alone. The half-maximal effective concentration (EC50) of each cell line was calculated 
as an indicator of response to the compound, respectively. 
 
To elucidate whether SGK1 overexpression exhibits a protective effect on chemotherapy 
treatment, the same setup was tested in Daoy and UW228-3 cells with or without 
overxpressing SGK1. Subsequently, dose response curves for transduced medullo-
blastoma cells were assessed, separately for either pLVX-SGK1-HA containing cells or 
empty-vector controls. Again, the EC50 was calculated as an indicator of response to the 
compound, respectively (Figure 19). After comparing the results within each cell line, 
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SGK1 seems to play a role in mediation of resistance against 4-hydroperoxycyclo-
phosphamide or lomustine in UW228-3 medulloblastoma cell lines. Minor effects were 
obtained for Daoy cells. These results still have to be validated in repeated experiments. 
 
 
Figure 19 Dose response curves of medulloblastoma cells with or without overexpressing SGK1 
exposed to 4-HC and CCNU for 48h, respectively. A-D) Depicted is the relative metabolic activity of Daoy 
(A and C) and UW228-3 (B and D) medulloblastoma cells transduced with respective pLVX-constructs after 
48h exposure to varying concentrations of 4-HC or CCNU as indicated, using MTS-assay. The values are 
means ± SD of technical triplicates from a single experiment and plotted relative to control cells treated with 
vehicle alone. The half-maximal effective concentration (EC50) of each cell line with (red) or without (blue) 
overexpressing SGK1 was calculated as an indicator of response to the compound, respectively. 
 
3.4 LENTIVIRUS-­‐MEDIATED	  KNOCKDOWN	  OF	  SGK1	  INDUCES	  APOPTOSIS	  IN	  
MEDULLOBLASTOMA	  CELL	  LINES	  
To determine the effects of the specific inhibition of SGK1 expression, lentivirus-
mediated knockdown of SGK1 via RNA interference (RNAi) in medulloblastoma cell lines 
was performed. Daoy and UW228-3 cells were choosen as model based on their high 
endogenous SGK1 levels (mRNA and protein; Figure 13). Five days post transduction, 
decreased protein levels were measured. Using up to five different shRNAs targeting 
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SGK1, knockdown efficiencies of 50 - 90% were achieved as assessed by Western blot 
analysis. Non-targeting shRNA was used as a control. 
 
 
 
 
Figure 20 Apoptosis and cell cycle analysis of UW228-3 cells after efficient shRNA-mediated 
knockdown of SGK1. Western blot analysis stained for SGK1 and β-ACTIN (housekeeping protein) 
showing decreased SGK1 protein expression levels five days post transduction of UW228-3 cells with a set 
of five different shRNAs targeting SGK1 compared to non-targeting control (MOI 10). Seven days post 
transduction cell cycle was measured by FACS analysis as described by Nicoletti et al.195. Sub G1-fractions 
representing the percentage of apoptotic cell numbers were reproducibly higher in all SGK1-silenced cells. 
The values are means ± SD of three independent experiments. 
 
Apoptosis and cell cycle analyses were performed seven days post transduction on cells 
stably expressing either one of the shRNAs against SGK1 or non-targeting shRNA. The 
percentages of extracted nuclei after propidium iodide staining (indicating DNA content) 
was measured by FACS analysis as described by Nicoletti et al.195. The assay revealed 
DNA content representing certain cell cycle phases (Sub G1, G1, S, G2/M) respectively. 
Apoptotic fractions (Sub G1) were significantly and reproducibly higher in all SGK1 
silenced cells compared to controls (Figure 20 and Figure 21). 
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Figure 21 Apoptosis and cell cycle analysis of Daoy cells after efficient shRNA-mediated knockdown 
of SGK1. Western blot analysis stained for SGK1 and β-ACTIN (housekeeping protein) showing decreased 
SGK1 protein expression levels five days post transduction of Daoy cells with a set of four different shRNAs 
targeting SGK1 compared to non-targeting control (MOI 10). Seven days post transduction cell cycle was 
measured by FACS analysis as described by Nicoletti et al.195 Sub G1-fractions representing the percentage 
of apoptotic cell numbers were higher in all SGK1-silenced cells. The values were obtained from a single 
experiment. 
 
These results showing survival of Daoy and UW228-3 cells is dependent on SGK1 
expression, raised the question whether SGK1 downregulation has a supportive effect on 
irradiation-induced apoptosis. Thus, stable knockdown of SGK1 was performed three 
days prior to irradiation at the doses indicated. Annexin V-PE/7AAD staining served as 
apoptosis assay, FACS measurement was conducted five days post transduction. Dose-
dependent increase of irradiation-induced apoptosis was detected. In non-irradiated 
cells, the pure effect of efficient SGK1 knockdown on apoptosis rates is shown, 
confirming the results presented in Figure 20 and Figure 21. Enhanced apoptosis could 
be achieved by irradiation of SGK1-silenced cells. Regarding the calculated ratios of 
means normalized to non-targeting controls at different irradiation doses, the experiment 
revealed an additive effect on apoptosis induction concerning irradiation when combined 
with gene silencing of SGK1 (Figure 22). Consequently, no synergistic effect was 
observed. 
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Figure 22 Determination of apoptosis rates in medulloblastoma cells after shRNA-mediated 
knockdown of SGK1 exposed to irradiation at the doses indicated. A-D) showing apoptosis assay on 
freshly harvested medulloblastoma cells stained with Annexin V and 7-AAD for early and late apoptosis, 
respectively. FACS analysis was performed five days post transduction with shRNAs targeting SGK1 and 
non-targeting control. ShRNA targeting BCL2 was used as a positive control for apoptosis induction. A) and 
C) represent apoptosis rates obtained from transduced Daoy and UW228-3 cells exposed to irradiation at 
different doses three days post transduction. The values are means ± SD of three independent experiments. 
The numbers at the bottom indicate ratios of means normalized to non-targeting controls at different 
irradiation doses. B) and D) showing exemplarily dot plot graphes of the FACS measurement.  
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3.5 PHARMACOLOGICAL	  INHIBITION	  OF	  SGK1	  BY	  A	  SMALL	  MOLECULE	  
(GSK650394)	  REDUCES	  CELL	  VIABILITY	  IN	  VITRO	  
To evaluate the role of SGK1 as a potential candidate for targeted drug therapy in 
medulloblastoma, the effect of administration of the SGK1 antagonist GSK650394 was 
tested in a panel of medullblastoma cell lines. This multi-kinase inhibitor had been 
developed as a prostate cancer therapeutic and was recently shown to effectively 
abrogate androgen-induced proliferation of prostate cancer cell lines. The selectivity of 
GSK650394 for SGK1 over that of Akt and other related kinases proved to be >30-fold, 
and it was >60-fold more selective for SGK1 over the upstream AGC kinase PDK1199. 
 
 
Figure 23 Determination of apoptosis rates in various medulloblastoma cell lines after pharma-
cological inhibition of SGK1. Cells were either treated with the SGK1 antagonist GSK650394 (10µM) 
or/and dexamethasone (1µM) or left untreated (vehicle alone) five days prior to FACS analysis. Αpoptosis 
assay was performed on freshly harvested cells stained with Annexin V and 7-AAD for early and late 
apoptosis, respectively. Shown are percentages of apoptotic cell populations. All medulloblastoma cells lines 
responded on GSK650394 exposure with an increase of apoptosis induction (grey bars). In Daoy and 
UW228-3 cells a partial rescue by dexamethasone could be achieved (black bars). The values are means ± 
SD of three independent experiments. 
 
A significant pro-apoptotic impact of the compound on tumor cells upon SGK1 inhibition 
was observed in all investigated cell lines in a dose- and time-dependent manner. The 
half-maximal effective concentration (EC50) after a 5-day exposure was calculated to 
assess the response of individual cell lines to the administered substance (data not 
shown). EC50 values ranged from 4 μM in DAOY cells to 9 μM in the UW228 cell lines, 
  
	   Results 	  	   	  
72 
being more resistant to the compound than all other cell lines tested likely due to 
harboring a high-level focal amplification of the SGK1 gene locus. For determination of 
apoptosis rates in various medulloblastoma cell lines after pharmacological inhibition of 
SGK1, cells were either treated with the SGK1 antagonist GSK650394 (10μM) with or 
without co-treatment with Dexamethasone (1μM) or left untreated (vehicle alone) five 
days prior to FACS analysis. All cell lines responded to GSK650394 exposure with an 
increase of apoptosis. In Daoy and UW228-3 cell lines, a partial rescue by 
dexamethasone could be achieved as indicated by the black bars in Figure 23. 
 
3.6 NDRG1	  IS	  A	  DIRECT	  DOWNSTREAM	  TARGET	  OF	  SGK1	  
Although various targets of SGK1 have been identified during the last years, the 
biological pathways altered by SGK1 signaling in medulloblastoma remain subject of 
further investigation. Murray et al. identified threonine residues in the n-myc downstream-
regulated gene 1 protein (NDRG1-Thr346/356/366) that are phosphorylated by SGK1 but 
not by related kinases142. In order to explore SGK1 activity in medulloblastoma cells after 
lentivirus-mediated SGK1 modulation, phosphorylation status of NDRG1 was monitored 
using Western blot analysis. Accordingly, either specific knockdown of SGK1 using 
lentivirus-mediated RNAi or stable SGK1 overexpression was achieved in Daoy and 
UW228-3 cells. Non-targeting shRNA or empty vector were used as controls. Increase or 
decrease in phosphorylation levels should be a global effect in SGK1 silenced or 
overexpressing cells, respectively. Following Western blot analysis of total protein 
lysates, antibodies detecting SGK1, NDRG1, phospho-NDRG1 (Thr346) and β-ACTIN 
(loading control) were used to assess individual expression levels. The expression 
pattern of SGK1 changed according to the modulation, decrease upon efficient 
knockdown of SGK1 and strong upregulation upon overexpression, as expected and 
previously shown. Investigation of the phosphorylation site of NDRG1 at Thr346 revealed 
a decreased phosphorylation signal in SGK1 downregulated cells compared to non-
targeting control (Figure 24 B). After overexpression of pLVX SGK1-HA, NDRG1 
phosphorylation levels (Thr346) were highly elevated in comparison to empty vector 
control. Furthermore, the same pattern of down- or upregulation of SGK1 was observed 
in total NDRG1 protein levels. Taken together, NDRG1 is directly co-regulated with 
SGK1 on protein levels and constitutes a direct phosphorylation target of SGK1, 
indicating its activity in medulloblastoma cell lines (Figure 24 B). 
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In addition, subgroup-specific gene expression of NDRG1 was determined in the same 
patient samples shown in Figure 11 A. This dataset (n=302) integrated different cohorts 
from the Heidelberg, Amsterdam, Paris and Cambridge series. Access was provided by 
the microarray analysis and visualization platform ’R2’ comprising untransformed, non-
normalized NDRG1 gene expression values of medulloblastoma subgroups. In contrast 
to protein expression, NDRG1 was not co-regulated with SGK1 on mRNA level as 
indicated by comparing Figure 24 A with Figure 11 A. 
 
 
Figure 24 A) Subgroup-specific gene expression pattern of NDRG1 in medulloblastoma. mRNA 
expression profiles were accessible via microarray analysis and visualization platform ‘R2’. Untransformed, 
non-normalized NDRG1 gene expression values of medulloblastoma samples (n=302), initially generated on 
Affymetrix gene expression arrays from different data sets were combined. Statistical significance was 
calculated using one-way ANOVA (p<0.0001). B) NDRG1 is a direct downstream target of SGK1. 
Western blot analysis showing decreased or elevated SGK1 protein expression levels five days post 
transduction of Daoy and UW228-3 cells after respective SGK1 modulation. Medulloblastoma cells were 
either transduced (MOI 10) with two different shRNAs targeting SGK1 to achieve an efficient knockdown of 
SGK1 or with pLVX-constructs for overexpressing SGK1. Staining for a phosphorylation-specific site of 
NDRG1 on Thr346 revealed a decreased phosphorylation signal in SGK1 downregulated cells compared to 
non-targeting control. After overexpression of pLVX SGK1-HA, NDRG1 phosphorylation on Thr346 was 
strongly enhanced in comparison to empty vector control. Moreover, the same pattern of down- or 
upregulation of SGK1 was observed in total NDRG1 protein levels. 
 
3.7 EXPRESSION	  PROFILING:	  DEREGULATED	  GENES	  AFTER	  SGK1	  
KNOCKDOWN	  
In order to discover novel molecular functions of SGK1, which might complement the 
phenotypic results, genome wide mRNA expression analyses on Agilent microarrays 
(Whole Human Genome Microarray Kit, 4x44K, Agilent) were performed. To learn more 
about genes and pathways that are differentially regulated upon SGK1 knockdown in 
medulloblastoma cells, RNA of transduced Daoy and UW228-3 cells was isolated five 
days post transduction. The RNA obtained from cells containing either shRNA E8 or 
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shRNA E9, both targeting SGK1, was labeled with a fluorophor and hybridized against 
labeled RNA of cells transduced with non-targeting shRNA on the array. After scanning 
the microrrays, the raw intensity data were preprocessed with the in-house platform 
ChipYard. The extracted list contained log2-ratios of normalized expression values. 
Annotation of oligonucleotide probes on gene expression arrays was retrieved via the 
PIMS© database (version: 1.26.1) by alignment of utilized sequences to EnsEMBL 
database version 60. Only unique valid oligonucleotides, meaning those which could be 
assigned to one definite gene, were included for the following analyses. Each list was 
sorted according to log2-ratios and the rank product over all experiments was calculated 
for each probe with the R-based software RankProd (http://bioinformatics.oxford-
journals.org/content/22/22/2825.full).This approach modifies and extendes the rank 
product method proposed by Breitling et al.200. Using a percentage of false predictions 
(PFP) cutoff of 0.1 for the fold-change related rank product upon SGK1 knockdown, 172 
genes were scored up- and 288 genes were downregulated (top 50 are shown in 
Supplementary Table 3 and Supplementary Table 4). To determine overrepresented 
pathways, the up- and downregulated candidates were examined for an over-
representation of annotations with Gene Ontology terms, KEGG pathways and the entire 
set of canonical pathways from the Broad Institute’s Molecular Signatures Database 
(MSigDB v3.0; http://www.broadinstitute.org/gsea/msigdb/index.jsp). As a reference, all 
uniquely assigned possibly measurable genes from the arrays were used. Significant 
annotations were identified according to the relation of total genes versus deregulated 
genes in a pathway by Fisher’s exact test with Bonferroni’s correction method for 
multiple testing. Annotations with corrected p-values below or equal to 0.05 were 
considered to be significant. Using Gene Ontology biological process analysis, various 
enriched annotations were found for downregulated genes (n=288) upon SGK1 
knockdown. Genes involved in e.g. blood vessel development, response to type I 
interferon and extracellular matrix organization were significantly enriched (Figure 25). 
Analysis of upregulated genes (n=172) after SGK1 knockdown revealed pathways 
involved in cell proliferation, developmental processes and phosphorylation of STAT5 
protein (Table 3). Gene Ontology molecular function analysis identified genes playing a 
role for growth factor and cytokine activity, and organization of the extracellular matrix 
(Table 4). No significant enrichments were determined by usage of KEGG pathway 
analysis and MSig database.  
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Figure 25 Enriched annotations of downregulated genes (n=288) after SGK1 knockdown using Gene 
Ontology biological process analysis. Number of downregulated genes in respective terms and corrected 
p-values are given, significant ones are shown in green. This bioinformatic analysis was performed in 
collaboration with Dr. M. Zapatka and Dr. R. Piro, DKFZ, Heidelberg. 
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Table 3 Enriched annotations of upregulated genes (n=172) after SGK1 knockdown using Gene 
Ontology biological process analysis. This bioinformatic analysis was performed in collaboration with Dr. 
M. Zapatka and Dr. R. Piro, DKFZ, Heidelberg. 
Annotation Number of 
genes 
Corrected 
p value 
GO term: Biological process 
GO:0042127 28 0.006 regulation of cell proliferation 
GO:0051239 33 0.02 regulation of multicellular organismal process 
GO:0051094 19 0.02 positive regulation of developmental process 
GO:0042522 4 0.03 regulation of tyrosine phosphorylation of Stat5 protein 
 
 
Table 4 Enriched annotations of up- and downregulated genes (n=172; n=288) after SGK1 
knockdown using Gene Ontology molecular function analysis. Upregulated genes are shown in red;  
downregulated genes are shown in green. This bioinformatic analysis was performed in collaboration with 
Dr. M. Zapatka and Dr. R. Piro, DKFZ, Heidelberg. 
Annotation Up- and downregulated genes Corrected 
p value 
GO term: Molecular 
function 
GO:0070851 CSF2, FGF5, HBEGF, IL1A, IL1B, IL2, 
ITGB3 
0.02 growth factor receptor 
binding 
GO:0008083 CSF2, ESM1,  FGF5, GDNF, HBEGF, 
IL1B, IL2, NRG1 
0.03 growth factor activity 
GO:0005125 CSF2, EDN1, IL1A, IL1B, IL2, IL8, 
IL23A8, NRG1 
0.03 cytokine activity 
GO:0005201 BGN, CHI3L1, COL11A1, COL12A1, 
COL14A1, COL1A2, COL5A1, COL8A2, 
FBLN1, FN1, MGP 
3,00E-05 
 
extracellular matrix  
 
Furthermore, enrichment of total transcription factor binding affinities201,202 in a region of 
1500 bp upstream to 500 bp downstream of the transcriptional start site (TSS) in the up- 
and downregulated candidates was investigated using a rank product score combined 
with an estimation of the false discovery rate (FDR) based on 10.000 random candidate 
sets. In doing so, binding sites for nine transcription factors were found to be significantly 
enriched in the downregulated gene set (n=288), whereas no significant enrichment was 
found in the upregulated genes (n=172), shown in Table 5. 
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Table 5 Enrichment of total transcription factor binding affinities. A region of 1500 bp up-stream to 500 
bp downstream of the transcriptional start site (TSS) in the downregulated candidates was investigated using 
a rank product score combined with an estimation of the false discovery rate (FDR) based on 10.000 random 
candidate sets. This bioinformatic analysis was performed in collaboration with Dr. M. Zapatka and Dr. R. 
Piro, DKFZ, Heidelberg. 
Transcription factor False discovery rate (FDR)  
MZF1_1-4 0.002 
TFAP2A 0.002 
MZF1_5-13 0.026 
Egr1 0.034 
SP1 0.058 
Mafb 0.059 
REST 0.064 
PLAG1 0.081 
RREB1 0.076 
 
 
The transcription factor ras responsive element binding protein 1 (RREB1) is co-
expressed with SGK1 across medulloblastoma subgroups in expression profiling data 
sets (Figure 26; Figure 11A), whereas the other predicted transcription factors were not 
differentially expressed between molecular subgroups (Table 5; expression data not 
shown).  
 
 
 
Figure 26 Subgroup-specific gene expression pattern of the transcription factor RREB1 in 
medulloblastoma. mRNA expression profiles were accessible via microarray analysis and visualization 
platform ‘R2’. Untransformed, non-normalized RREB1 gene expression values of medulloblastoma samples 
(n=302), initially generated on Affymetrix gene expression arrays from different data sets were combined. 
Statistical significance was calculated using one-way ANOVA (p<0.0001). 
 
 
  
	   Discussion 	  	   	  
78 
4 DISCUSSION	  
Medulloblastoma is the most frequent malignant brain tumor occuring in childhood and 
constitutes one of the leading causes of childhood mortality. Current treatment decisions 
are based on histological tumor appearance, combined with clinical parameters such as 
patient age, presence of metastatic disease at primary diagnosis, and extend of surgical 
resection. Due to these factors, patients are stratified into clinical risk groups with distinct 
intensity of therapy (standard-/low-risk and high-risk). Multimodal therapy approaches 
include surgical resection, radiotherapy of the entire brain and spinal cord (in patients 
aged >3 years), followed by multi-agent chemotherapy. 
Therapeutic achievements of the last decades for patients suffering from medullo-
blastoma have enabled 5-year overall survival (OS) rates of approximately 80% to 85% 
in children diagnosed with standard-risk disease nowadays104, and up to 70% 5-year OS 
in children classified with high-risk medulloblastoma105. Unfortunately, these remarkable 
improvement in clinical outcome is accompanied by marked quality of life issues, as 
many survivors experience significant intellectual and long-term neurological disabilities 
secondary to both disease and therapy106-109. Interestingly, the systematic use of 
empirically based cytotoxic treatment regimens has not been adapted to our increased 
understanding of medulloblastoma biology and development of novel therapies in recent 
years, yet. For novel treatment approaches, it is important to consider that medullo-
blastoma comprises at least four distinct molecular subgroups with entirely different 
clinical and biological features84,85,110. There is strong evidence that clinical care of 
patients could be improved by the identification of new molecular biomarkers enabling 
appropriate stratification, and use of patient-specific, targeted anti-cancer agents87. 
Recent studies of retrospectively collected medulloblastoma samples have identified 
important molecular alterations and prognostic subgroups of this disease59,84-
86,88,99,110,111,203. After preliminary work demonstrating that DNA copy-number aberrations 
affecting chromosome 6q clearly define clinical and biological subgroups of 
medulloblastoma patients111, this study aimed at identifying candidate gene(s) targeted 
by these aberrations. This investigation was essential to get a better understanding of 
the underlying molecular pathomechanism, accounting for the astonishing differences in 
patient outcome according to chromosome 6q status. 
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This thesis focused on SGK1, an attractive candidate gene on chromosome 6, which 
might potentially serve both as a prognostic marker and a novel therapeutic target in 
medulloblastoma.  
 
4.1 SGK1	  IS	  A	  PROGNOSTIC	  MARKER	  FOR	  HIGH-­‐RISK-­‐MEDULLOBLASTOMA	  
Integrative genome-wide analyses of DNA copy-number status, transcriptome profiles, 
and clinical follow-up data of 64 medulloblastoma samples revealed SGK1 as a 
promising candidate oncogene in medulloblastoma. SGK1 was identified based on its 
significant overexpression in tumors harboring a gain of chromosome 6q, compared to 
medulloblastomas with a balanced chromosome 6q, or monosomy 6. Positive correlation 
of SGK1 mRNA expression with chromosome 6q copy-number status was much 
stronger than expected by a simple gene-dosage effect (Figure 10), hinting at a 
functional impact of this kinase in medulloblastoma biology. Given that monosomy 6 is a 
genomic feature restricted to WNT medulloblastomas204, and gain of chromosome 6q 
seems be restricted to high-risk tumors (Group 3 and Group 4), SGK1 mRNA levels were 
further evaluated across the molecular medulloblastoma subgroups as suggested by 
Northcott et al.84. Subgroup-specific SGK1 expression patterns could be confirmed in our 
cohort as well as in three other independent data sets, demonstrating lowest expression 
levels in WNT and SHH tumors (associated with good/excellent prognosis), and 
overexpression in medulloblastomas allocated to Group 3 and Group 4 (characterized by 
poor prognosis) (Figure 11 A). Moreover, significantly higher SGK1 gene body and 
3’UTR methylation was found on several CpG sites in the WNT and SHH-subgroups, 
whereas almost no methylation in the 3’ end of SGK1 was observed in Group 3 and 
Group 4 tumors (Figure 12). These results indicate a clear negative correlation of SGK1 
mRNA expression levels and extent of methylation (R=-0.8), albeit the underlying 
mechanism of gene body and 3’UTR methylation still remains unclear.  
CpG sites are often grouped in clusters called CpG islands, which are predominantly 
present in the 5' regulatory regions of many genes. In several disease processes, such 
as cancer, gene promoter CpG islands acquire abnormal hypermethylation resulting in 
transcriptional silencing that can be inherited by daughter cells following cell division. 
Alterations in DNA methylation patterns, particulary associated with tumor suppressor 
genes, have been recognized as an important component in the development of 
cancer205-208. In contrast to gene silencing by hypermethylated promoter regions, gene-
body methylation has been observed in Arabidopsis thaliana, where it is associated with 
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active genes, therefore hypothesized to suppress spurious initiation of transcription 
within active genes209,210, and a similar function may exist in mammals. It has long been 
known that also in certain mammalian genes, methylation of gene bodies is positively 
correlated with elevated gene expression211,212. The underlying mechanism of SGK1 
expression being negatively correlated with gene body methylation is not known yet. 
Hypermethylation of the gene body could influence the local chromatin structure to 
hinder transcription or alternatively, methyl CpG binding proteins, which are repressive 
for transcription, could be attracted213. 
 
The strict correlation of SGK1 expression with prognosis renders abundant SGK1 
expression a promising biomarker for high-risk medulloblastoma. The prognostic value of 
this novel finding was validated also on protein levels using an immunohistochemical 
approach. An independent large tumor cohort represented on a tissue microarray 
showed significant association of high SGK1 expression and poor overall survival 
(p=0.0168) (Figure 11 B). The application of an immunohistochemistry-based method to 
detect this novel biomarker confers the suitability for routine usage in a diagnostic 
neuropathological setting. While overexpression of SGK1 has previously been described 
in some hepatocellular carcinomas as well as in a high proportion of breast cancer 
specimens157-159,165, this is the first report providing evidence for its prognostic 
significance in tumors. 
 
4.2 SGK1	  IS	  A	  POTENTIAL	  DRUG	  TARGET	  IN	  MEDULLOBLASTOMA	  
The implication of SGK1 in tumorigenesis has previously been described in various solid 
tumors158-161. Several reports suggest a functional role of SGK1 in tumor biology by 
promoting cell survival and cell-cycle progression124,162.  
 
4.2.1 Knockdown of SGK1 Induces Apoptosis in vitro 
Since abundant expression of SGK1 in high-risk medulloblastoma is associated with 
poor overall survival of patients in contrast to cases with low SGK1 expression and 
excellent prognosis (Figure 11), it was highly interesting to assess the potential 
functional role of SGK1 in medulloblastoma pathogenesis. Lentivirus-mediated 
knockdown of SGK1 in the medulloblastoma cell lines Daoy and UW228-3 dramatically 
induced apoptosis (Figure 20 and Figure 21). This phenotype points to an essential role 
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for SGK1 in cell survival in medulloblastoma. The apoptosis rates could be increased in 
combination with irradiation three days post transduction in an additive, but not in a 
synergistic manner (Figure 22). 
Interestingly, as a close homologue to anti-apoptotic kinase AKT in both structure and 
function, SGK1 was described to function complementary to AKT in promoting cell 
survival by directly phosphorylating and inactivating the proapoptotic proteins forkhead 
transcrition factor FKHRL1 (FOXO3a) and BCL2-associated agonist of cell death 
(BAD)125,168. Survival factors, acting through kinases such as SGK1, AKT and PKA, 
induce endogenous BAD phosphorylation at three evolutionarily conserved sites (Ser-
112, Ser-136, and Ser-155) leading to loss of the ability of BAD to heterodimerize with 
the survival proteins BCL-XL or BCL-2. Phosphorylated BAD binds instead to 14-3-3 
protein and is sequestered in the cytoplasm214,215. Can phosphorylation of BAD explain 
all of the apoptosis-inhibitory effects of SGK1? The answer is ‘probably not’, for various 
reasons. First, BAD is not a ubiquitously expressed protein, cell types that fail to express 
it are still protected by SGK1 or PKB/AKT216. Second, SGK1 phosphorylates several 
other proteins that are likely to regulate apoptosis, including e.g. FOXO3a, which is 
sequestered in the cytoplasm upon phosphorylation, resulting in an attenuation of its 
ability to transcribe pro-apoptotic genes such as Fas ligand214. 
 
4.2.2 Overexpression of SGK1 Induces Chemotherapy Resistance 
and Increases Migration Rates in vitro 
Given the described pro-survial and cell cycle progression mediating effects of SGK1, 
phenotypic assays were also performed after stable SGK1 overexpression in the 
medulloblastoma cell lines Daoy and UW228-3. No effects on proliferation or inhibition of 
irradiation-induced apoptosis were detected in both cell lines (Figure 14, Figure 16, 
Figure 17), but in terms of resistance against alkylating agents interesting evidence was 
obtained. It seems that overexpression of SGK1 could have a protective role in response 
to 4-HC and CCNU in UW228-3 cells, because the EC50 value was increased in cells 
overexpressing SGK1 compared to their control counterparts, whereas only minor effects 
were detected in Daoy cells (Figure 19). This result has to be considered with caution, 
because the experiment was only performed once and it turned out that slightly less 
control cells were seeded than SGK1-overexpressing cells, which also could influence 
chemotherapy sensitivity. Hence, the result still has to be validated in future experiments. 
In addition, Daoy and UW228-3 medulloblastoma cells overexpressing SGK1 showed 
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increased migration rates as compared to control cells (Figure 15 C, D). These 
phenotypes due to high SGK1 expression levels in vitro might also reflect the aggressive 
characteristics of high-risk medulloblastomas (Group 3 and Group 4) in vivo. 
 
4.2.3 How Could the Obtained Phenotypes be Mediated by SGK1? 
To shed light on deregulated pathways and genes upon SGK1 knockdown, mRNA 
expression profiling was performed. Indeed, on transcriptome level only indirect effects 
could be detected. Microarray-based analysis revealed differentially expressed indirect 
targets after SGK1 knockdown, 172 genes were up- and 288 genes were downregulated 
(Top 50 are shown in Supplementary Table 3 and Supplementary Table 4). Gene 
Ontology annotations revealed significant enrichment for genes playing a role in blood 
vessel development, response to type I interferon, extracellular matrix organization, cell 
proliferation, developmental processes, phosphorylation of STAT5 protein, and growth 
factor- and cytokine activity (Figure 25, Table 3, Table 4). SGK1 seems to serve as an 
integration point for diverse signaling pathways. In fact, the obtained results provide a 
snapshot on deregulated pathways, which also could come up due to secondary effects. 
There are various mechanisms described in the literature, which could explain the 
obtained phenotypes upon SGK1 modulation in association with these deregulated 
pathways as discussed in the following section. 
 
On transcriptional level, SGK1 has been shown to be upregulated upon dexamethasone 
treatment due to activation of the glucocorticoid receptor, mediated by a glucocorticoid 
response element (GRE) within the SGK1 promoter126,130. SGK1 protein levels are tightly 
balanced by ubiquitination and regulation of SGK1 activity is mediated by PI3K-
signaling121. There are two conserved phosphorylation sites present in the activation loop 
of SGK1 and the hydrophobic domain at its C-terminus (Thr-256 and Ser-422), which 
both have to be phosphorylated for full kinase activity116-119. Lentivirus-mediated 
modulation of SGK1 was monitored on protein levels showing elevated SGK1 expression 
and moreover SGK1 activity was confirmed by increased phosphorylation of its 
downstream target NDRG1. Thus, protein expression and phosphorylation (Thr346) of 
NDRG1 are directly co-regulated with SGK1 in medulloblastoma cell lines (Figure 24 B). 
 
NDRG1 was often described to play an ambiguous role in cancer-related processes. On 
one hand, NDRG1 is one of the most upregulated genes in hepatocellular carcinoma and 
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high expression levels of NDRG1 were found to be significantly correlated with short 
overall survival, late tumor stage, large tumor size, the presence of vascular invasion, 
and high histological grade217. Furthermore, high NDRG1 expression is related to poor 
prognosis and angiogenesis in cervical adenocarcinoma and pancreatic cancer218,219. On 
the other hand, in other human malignancies such as gastric cancer, cervical cancer, 
and pancreatic cancers NDRG1 was suggested as a putative angiogenesis-suppressor 
gene218-220. Therefore, NDRG1 may promote or suppress tumor angiogenesis dependent 
on the cellular context221. 
For example, in human lung cancer cells, NDRG1 knockdown suppressed production of 
the potent angiogenic factors VEGF and CXCL-8, suggesting the involvement of reduced 
expression of such angiogenic factors in reduced angiogenesis resulting from NDRG1 
knockdown222. Interestingly, the gene encoding cytokine CXCL-12 was downregulated 
upon SGK1 knockdown (Supplementary Table 4), was reported to act pro-metastatic via 
binding to the chemokine receptors CXCR-4 and CXCR-7223. It still remains unclear why 
NDRG1 could have a double-edged influence on cancer progression. NDRG1 is reported 
to be a multiphosphorylated protein224,225, while the role of phosphorylation is unknown 
but speculated to be related to the multitude of physiological functions of NDRG1222. 
Recent studies in glioblastoma cell lines revealed elevated NDRG1 phosphorylation 
levels in Temozolomide-resistant cell populations and NDRG1 overexpression was 
associated with poor overall survival in conventionally treated glioblastoma patients 
(unpublished data from Prof. W. Wick and J. Blaes, DKFZ, Heidelberg; personal 
communication). Therefore, NDRG1 could serve as a putative potential marker for 
chemotherapy resistance in glioblastoma. As shown above, NDRG1 and phosho-NDRG1 
(Thr346) are co-regulated with SGK1 upon SGK1 modulation in medulloblastoma cell 
lines (Figure 24 B). In contrast, on mRNA level NDRG1 is not co-regulated with SGK1 
(Figure 24 A). This discrepancy could indicate that regulation occurs post-translationally 
via SGK1, whereas the impact of NDRG1-phosphorylation by SGK1 in medulloblastoma 
still has to be unraveled. Thus, NDRG1 protein could play a crucial role in mediating the 
phenotypic effects and poor prognosis of SGK1 overexpression in vitro and in vivo, in 
addition to other signaling molecules, which are influenced by SGK1. 
 
Another central player in SGK1 downstream signaling could be integrin beta 3 (ITGB3). 
ITGB3 was upregulated (log2 ratio 1.5) upon SGK1 knockdown compared to control cells 
(Supplementary Table 3). Growing evidence supports a central role for cooperative 
signaling between integrins, growth factor receptors and cytokine receptors in many 
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aspects of tumor progression. This crosstalk not only regulates tumor cell adhesion, 
migration, invasion and survival, but also affects many aspects of the host response to 
cancer, in particular regarding the angiogenic endothelium226. Interestingly, another study 
on glioma cells revealed that the expression of pro-apoptotic ITGB3 was significantly 
downregulated in BCNU-resistant glioma cells and might be directly involved in the drug 
resistance of glioma cells. Subsequent dissection of signaling pathways denoted that 
extracellular signal-regulated kinase and unligated integrin-mediated cell death pathway 
may be involved in the pro-apoptotic role of ITGB3 in glioma cell death/survival and drug 
resistance227. Since BCNU is an alkylating drug, similar to CCNU, and ITGB3 was 
upregulated upon SGK1 knockdown, this might be another mechanism in mediating drug 
resistance in medulloblastoma. The ITGB3 expression status of medulloblastoma cells 
overexpressing SGK1 as well as the drug sensitivity of medulloblastoma cells after 
SGK1 knockdown needs to be further investigated. 
 
Furthermore, integrins are crucial for cell migration and invasion228,229. They can bind to 
components of the extracellular matrix (ECM), thereby providing the traction that is 
necessary for cell motility and invasion and also remodelling of the ECM is controlled by 
integrins, which regulate the localization and activity of proteases230. Additionaly, 
deregulated integrin expression could also provide a reasonable mechanism for 
apoptosis-induction after depleting SGK1. Integrins are cell adhesion receptors that 
regulate cell survival and migration and can paradoxically initiate pro-survival as well as 
pro-apoptotic signals. Which pathway is more active depends on the ligation state of the 
respective surface integrins expressed by a given cell226. In adherent cells, in which 
many of the integrins are unligated, the unligated integrins initiate cleavage of caspase 8, 
triggering apoptosis through integrin-mediated death (IMD). At complete loss of 
adhesion, cell death is initiated through a process termed anoikis169,226. Consistent with 
this, a recent study showed that unligated integrin beta 3 (ITGB3) induced apoptosis in 
various solid tumors. Unligated integrin on the surface of adherent cells recruits and 
activates caspase 8, which in turn activates the proapoptotic factors Bid, Bax, and p53, 
and inhibits antiapoptotic Bcl-2. It was suggested that over-expression of ITGB3 may 
produce unligated ITGB3, which acts as negative modulator of cell survival, thereby 
leading to IMD-like cell death231. Notably, it has been previously shown, that activated 
SGK1 blocks apoptosis induced by loss of integrin-mediated cell attachment (anoikis)168.  
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In this study, deregulated genes upon SGK1 knockdown were investigated on whether 
they share common transcription factor binding sites. Enrichment analysis revealed a 
significant overrepresentation of nine transcription factors likely to bind in regulatory 
regions of the candidate genes (Table 5). An interesting finding was, that ras responsive 
element binding protein 1 (RREB1) is co-expressed with SGK1 across medulloblastoma 
subgroups (Figure 26), whereas the other predicted transcription factors were not 
differentially expressed between subgroups. A possible explanation for this co-regulation 
with SGK1 in medulloblastoma is provided by the gene locus of RREB1 on 6p25, which 
could also be affected in monosomy or trisomy of chromosome 6 tumors, as it is the 
case for SGK1 on 6q23. Also a central role in SGK1 mediated signaling could be related 
to this transcription factor, as its effect became visible by the expression profiling 
experiment. RREB1 binds specifically to the RAS-responsive elements (RRE) of gene 
promoters, and activated Ras/Raf- signaling cascade prevents apoptosis in response to 
growth factors and mitogens232. Interstingly, a recent report demonstrated that 
knockdown of the transcription factor RREB1 inhibits collective cell migration in a 
scratch-wound healing assay of breast cancer cells, suppresses surface activity, and 
leads to the formation of immobile, tightly adherent cell colonies. Therefore RREB1 has 
been described to play an essential role in reducing cell-cell adhesion of epithelial cells 
within an interconnected cell cluster, which try to undergo dynamic changes in cell 
shape233. RREB1 is differentially expressed across medulloblastoma subgroups showing 
the same pattern as SGK1 in expression profiling data sets (Figure 26). High RREB1 
levels correlate with Group 3 and Group 4 tumors which tend to metastasize and are 
associated with poor prognosis. 
 
4.2.4 Small Molecule Inhibitor GSK650394 Induces Apoptosis in 
Medulloblastoma Cell Lines 
Supporting the observations in primary tumors, the obtained phenotypes after SGK1 
modulation in vitro implicate a functional role of SGK1 in medulloblastoma pathogenesis, 
metastatic properties, and treatment response. These observations point to an eligibility 
exploiting SGK1 as promising drug target for the clinical management of medullo-
blastoma. To test whether SGK1 function could be inhibited pharmacologically with 
respect to clinical application, various well-established medulloblastoma cell lines were 
treated with a small molecule SGK1 inhibitor (GSK650394). The therapeutic potential of 
SGK1 antagonist GSK650394 was previously evaluated in vitro and has been shown to 
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effectively abrogate androgen-induced proliferation of prostate cancer cell lines199. The 
selectivity of GSK650394 for SGK1 over that of AKT and other related kinases proved to 
be >30-fold, and it was >60-fold more selective for SGK1 over the upstream AGC kinase 
PDK1199. A dramatic increase in apoptosis induction after exposing the cells for five days 
to the SGK1 antagonist GSK650394 (10μM) has been detected in all investigated 
medulloblastoma cell lines. Furthermore a partial rescue by co-administration of 
dexamethasone (1μM) could be achieved in Daoy and UW228-3 cell lines (Figure 23). 
Significant induction of SGK1 expression, accompanied by abundant SGK1 protein 
levels upon dexamethasone treatment was observed in well-established medullo-
blastoma cell lines (Figure 13 B).  
Protection from apoptosis and increased chemotherapy resistance after glucocorticoid 
treatment has previously been described in a broad variety of solid cancers including 
brain tumors. It was shown that dexamethasone treatment inhibits cisplatin and 5-
fluorouracil-induced apoptosis and promotes the growth of the malignant cells174. This 
phenomenon is associated with a glucocorticoid receptor-dependent, transcriptional 
induction of anti-apoptotic genes, including SGK1, which also protects breast cancer 
cells from growth factor starvation-induced apoptosis130,175. Nevertheless, glucocorticoids 
such as dexamethasone are clinically used in a supportive-care role for patients to 
effectively reduce peri-operative edema and furthermore to suppress nausea due to 
cancer chemotherapy or irradiation. However, no prospective clinical studies have 
assessed the effect of these steroids on the growth of solid tumors234-236. Since 
dexamethasone partially abrogated GSK650394 induced apoptosis (Figure 23), elevates 
SGK1 protein levels in medulloblastoma cell lines (Figure 13 B), and increases chemo-
resistance after SGK1-overexpression (Figure 19), glucocorticoid-induced protection may 
counteract chemotherapy in solid tumors236,237. Consequently, to cirumvent therapy 
resistance in clinical practice, administration of glucocorticoids in medulloblastoma 
therapy should be avoided or substituted by other adjuvant substances whenever 
possible. 
Taken together, the presented findings indicating a prognostic role of SGK1 over-
expression (Figure 11) combined with a more aggressive phenotype due to high SGK1 
levels (Figure 15; Figure 19) and inducibility of apoptosis due to loss of SGK1 function 
(Figure 20; Figure 21; Figure 23) provide strong evidence for SGK1 as novel therapeutic 
target in high-risk medulloblastomas. This specified therapeutic approach might support 
or even modify conventional therapy regimens to improve individual patient outcome and 
diminish side effects of conventional cytotoxic chemotherapy. 
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5 CONCLUSIONS	  AND	  OUTLOOK	  
Previous data showing that chromosome 6q status defines clinical subgroups for the 
outcome of medulloblastoma patients constituted the starting point of the molecular 
analyses performed in the present study. Global gene expression profiling and 
immunohistochemical examination of medulloblastoma samples identified SGK1 at 
chromosome band 6q23 as a novel prognostic marker and thus interesting candidate 
gene on chromosome 6. Functional analyses in vitro demonstrated that depletion of 
SGK1 function induces apoptosis, whereas ectopic overexpression of SGK1 results in 
increased migration. The obtained phenotypes after SGK1 modulation in vitro likely result 
from an interplay between diverse deregulated pathways including extracellular matrix 
organization, cell proliferation, developmental processes, blood vessel development, as 
well as growth factor- and cytokine activity. Despite the exact mechanisms still need to 
be unraveled, the findings provide strong in vitro evidence for the pivotal role of SGK1 in 
the pathogenesis of medulloblastoma. This highlights the importance of SGK1 as a 
valuable therapeutic target. At the same time, SGK1-overexpressing cells constitute a 
convenient in vitro model for high-risk medulloblastoma showing copy-number gain of 
chromosome 6q and consecutive overexpression of SGK1, which offers the possibility 
for pre-clinical evaluation of novel therapy options using pharmacological SGK1 inhibition 
or other more indirect ways of inhibiting the same pathway. Consequently, a mouse 
model for studying the impact of SGK1 in high-risk medulloblastoma in terms of 
microenvironment, angiogenesis, metastatic dissemination, and treatment response 
would be highly interesting. Given that high SGK1 expression is a frequent phenomenon 
in Group 3 and Group 4 tumors associated with poor prognosis, SGK1 comprises a 
potential drug target for affected medulloblastoma patients. Finally, a targeted therapy 
approach, adjusted to tumor biology, might open excellent prospects towards 
personalizing medulloblastoma therapy to improve individual outcome in the future. 
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Supplementary Table 1 Differentially expressed genes at chromosome 6q (top 50). 
Gene IDs Gene Symbols Log2-ratio  
(6q gain/6q loss) 
ENSG00000118487 Q9NQ15_HUMAN 6.651536953 
ENSG00000153157 SYCP2L 5.447362996 
ENSG00000164483 SAMD3 5.345623716 
ENSG00000112319 EYA4 4.790500393 
ENSG00000135298 BAI3 4.605965507 
ENSG00000188107 EGFL11 3.603930692 
ENSG00000091831 ESR1 3.498036550 
ENSG00000118515 SGK1 3.349049918 
ENSG00000112706 IMPG1 3.059895435 
ENSG00000111879 C6orf60 3.042582291 
ENSG00000112305 SMAP1 2.921533071 
ENSG00000135525 MAP7 2.832387863 
ENSG00000135541 AHI1 2.686615866 
ENSG00000025039 RRAGD 2.639821917 
ENSG00000164483 SAMD3 2.613126102 
ENSG00000025039 RRAGD 2.596957691 
ENSG00000137343 C6orf134 2.501169734 
ENSG00000111879 C6orf60 2.486942053 
ENSG00000146457 WTAP 2.419393757 
ENSG00000065609 SNAP91 2.372147244 
ENSG00000025039 RRAGD 2.268342020 
ENSG00000135314 KHDC1 2.239530546 
ENSG00000096093 EFHC1 2.156483994 
ENSG00000135324 C6orf117 2.105847550 
ENSG00000112297 AIM1 2.091820050 
ENSG00000111832 RWDD1 2.034385164 
ENSG00000135541 AHI1 2.001322446 
ENSG00000112305 SMAP1 1.992571868 
ENSG00000118402 ELOVL4 1.961008885 
ENSG00000135597 REPS1 1.948443673 
ENSG00000112245 PTP4A1 1.901299836 
ENSG00000196586 MYO6 1.885680113 
ENSG00000153721 CNKSR3 1.884202432 
ENSG00000185250 PPIL6 1.849514530 
ENSG00000196911 KPNA5 1.806668531 
ENSG00000132424 C6orf111 1.800259923 
ENSG00000177214 C6orf224  1.779916869 
ENSG00000074935 TUBE1 1.775791053 
ENSG00000168216 LMBRD1 1.769003083 
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ENSG00000112232 KHDRBS2 1.739712229 
ENSG00000085382 HACE1 1.728671305 
ENSG00000203756 CF191_HUMAN 1.722174483 
ENSG00000119899 SLC17A5 1.719022458 
ENSG00000118513 MYB 1.714005996 
ENSG00000203702 CF059_HUMAN 1.709510088 
ENSG00000188994 ZNF292 1.679441705 
ENSG00000112238 PRDM13 1.676516373 
ENSG00000079841 RIMS1 1.621929583 
ENSG00000004809 SLC22A16 1.569334375 
ENSG00000111880 RNGTT 1.550216488 
 
 
Supplementary Table 2 Differentially expressed genes at chromosome 6q (top 50). 
Gene IDs Gene Symbols ΔLog2-ratio  
(6q gain-6q loss) 
ENSG00000112232 KHDRBS2 5.44793313 
ENSG00000135298 BAI3 4.79385187 
ENSG00000164483 SAMD3 4.49516084 
ENSG00000187772 LIN28B 4.21778024 
ENSG00000118513 MYB 3.91671434 
ENSG00000118495 PLAGL1 3.57651389 
ENSG00000188107 EGFL11 3.48970246 
ENSG00000118515 SGK1 3.42792452 
ENSG00000112706 IMPG1 3.39238264 
ENSG00000118487 Q9NQ15_HUMAN 3.21677199 
ENSG00000213204 C6orf165 3.09191269 
ENSG00000152822 GRM1 2.85350262 
ENSG00000164483 SAMD3 2.83784063 
ENSG00000118514 ALDH8A1 2.70925952 
ENSG00000112238 PRDM13 2.69440944 
ENSG00000135541 AHI1 2.68323646 
ENSG00000112297 AIM1 2.64728773 
ENSG00000213204 C6orf165 2.52463487 
ENSG00000004809 SLC22A16 2.48251369 
ENSG00000187772 LIN28B 2.36494060 
ENSG00000172594 SMPDL3A 2.35684590 
ENSG00000198719 DLL1 2.35627865 
ENSG00000146166 GLULD1 2.35269745 
ENSG00000203734 C6orf91 2.35125778 
ENSG00000164442 CITED2 2.24430481 
ENSG00000178425 NT5DC1 2.22621111 
ENSG00000112339 HBS1L 2.22616358 
ENSG00000188994 ZNF292 2.20217315 
ENSG00000024862 CCDC28A 2.19786605 
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ENSG00000118495 PLAGL1 2.13867407 
ENSG00000196911 KPNA5 2.12920296 
ENSG00000111912 NCOA7 2.11746298 
ENSG00000049618 ARID1B 2.09846149 
ENSG00000085382 HACE1 2.09128243 
ENSG00000083097 DOPEY1 2.09080476 
ENSG00000177214 NP_775830.1 2.08627999 
ENSG00000116183; 
ENSG00000112245 
PAPPA2;PTP4A1 2.06406025 
ENSG00000026652 AGPAT4 2.04941124 
ENSG00000135597 REPS1 2.04364622 
ENSG00000065609 SNAP91 2.01824604 
ENSG00000112486 CCR6 2.01054462 
ENSG00000146263 C6orf167 2.00165799 
ENSG00000196586 MYO6 1.99995427 
ENSG00000154548 SRR35_HUMAN 1.94918374 
ENSG00000168438 CDC40 1.94375934 
ENSG00000196586 MYO6 1.91612585 
ENSG00000146411 SLC2A12 1.90527704 
ENSG00000111912 NCOA7 1.88184449 
ENSG00000118496 FBXO30 1.87804212 
ENSG00000135314 C6orf148 1.85990309 
 
 
Supplementary Table 3 Top 50 (total 172) upregulated genes upon SGK1 knockdown, fold change 
(knockdown/control) value indicates the mean over all experiments for respective probe. 
Agilent IDs Gene Symbols  Fold-change  (Log2-ratio) 
A_24_P337239 FGF5 2,6875 
A_24_P158089 SERPINE1 2,4275 
A_23_P101054 KRT34 2,1970 
A_23_P333228 MARCH4 2,0584 
A_23_P72096 IL1A 2,0097 
A_24_P119201 MBD2 1,9364 
A_23_P69810 AGPAT9 1,9162 
A_23_P123234 SERPINE1 1,9051 
A_24_P143118 SCML2 1,8548 
A_23_P79518 IL1B 1,7668 
A_23_P156826 C6orf105 1,7613 
A_23_P215956 MYC 1,7131 
A_23_P213319 ADAMTS6 1,6842 
A_23_P136493 NRG1 1,6787 
A_24_P397204 KCNIP4 1,6687 
A_23_P76078 IL23A 1,6616 
A_24_P926284 OFCC1 1,6374 
A_23_P317760 C6orf146 1,6128 
A_23_P212800 FGF5 1,6110 
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A_32_P87013 IL8 1,5719 
A_23_P106389 SEMA7A 1,5225 
A_23_P214821 EDN1 1,5102 
A_24_P355057 SLC13A1 1,5035 
A_24_P936899 C12orf63 1,5020 
A_23_P159325 ANGPTL4 1,5002 
A_23_P38519 ITGB3 1,4639 
A_24_P410498 WDFY4 1,4600 
A_24_P198044 ZNF483 1,4452 
A_24_P915734 C2orf82 1,4335 
A_23_P111311 AKAP12 1,4285 
A_23_P135381 SP5 1,4239 
A_32_P88555 ATF7 1,4215 
A_23_P118842 KRTAP1-5 1,4111 
A_24_P33895 ATF3 1,4065 
A_23_P34915 ATF3 1,3969 
A_23_P338479 CD274 1,3958 
A_23_P315815 NRG1 1,3764 
A_24_P193011 CCND1 1,3752 
A_23_P403488 NLRP10 1,3587 
A_24_P247738 DNAH8 1,3440 
A_23_P156861 RGS17 1,3389 
A_23_P214897 AKAP12 1,3278 
A_23_P25194 HRK 1,3267 
A_24_P459739  1,3262 
A_24_P307885 ERGIC1 1,3092 
A_32_P196193 PAQR9 1,3032 
A_24_P255233 AC100793.1 1,2998 
A_24_P14902 TAS2R42 1,2962 
A_23_P34366 HTR1D 1,2961 
A_23_P43197 CALB1 1,2937 
 
 
Supplementary Table 4 Top 50 (total 288) downregulated genes upon SGK1 knockdown, fold change 
(knockdown/control) value indicates the mean over all experiments for respective probe. 
Agilent IDs Gene Symbols  Fold-change  (Log2-ratio) 
A_23_P204286 MGP -3,3865 
A_23_P86470 CH25H -3,0962 
A_23_P170649 C8orf84 -3,0471 
A_23_P154605 SULF2 -3,0376 
A_24_P173823 PBX1 -3,0123 
A_23_P257307 SERPINA7 -2,9252 
A_23_P113351 SPARCL1 -2,8888 
A_23_P109322 PCP4 -2,8818 
A_23_P83134 GAS1 -2,8370 
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A_23_P91230 SLPI -2,8163 
A_24_P190472 SLPI -2,7682 
A_32_P134764 CDH6 -2,7134 
A_32_P188860 IL17RD -2,6920 
A_23_P206022 ITGA11 -2,6799 
A_23_P43164 SULF1 -2,6773 
A_23_P383009 IGFBP5 -2,6309 
A_23_P58676 C5orf23 -2,6214 
A_23_P110403 PDLIM3 -2,6205 
A_23_P213424 ENC1 -2,5899 
A_23_P6263 MX2 -2,5460 
A_23_P75299 LHPP -2,5200 
A_23_P201459 IFI6 -2,5186 
A_23_P19673 SGK1 -2,4970 
A_23_P34126 BGN -2,4882 
A_23_P24507 AP002004.1 -2,4737 
A_24_P277934 COL1A2 -2,4703 
A_23_P17345 MAFB -2,4673 
A_24_P347411 POSTN -2,4590 
A_23_P211631 FBLN1 -2,4555 
A_23_P28307 DHX57 -2,4527 
A_24_P306814 ASS1P9 -2,4526 
A_23_P61508 CHRNA9 -2,4487 
A_23_P2492 C1S -2,4165 
A_23_P137016 SAT1 -2,4161 
A_23_P121533 SPON2 -2,3892 
A_23_P216361 COL14A1 -2,3887 
A_23_P46045 RGS5 -2,3827 
A_24_P130363 C18orf1 -2,3659 
A_23_P18447 PPARGC1A -2,3626 
A_24_P246825 C6orf138 -2,3340 
A_32_P155026 NFIA -2,3294 
A_23_P207003 SEPT_4 -2,3292 
A_23_P371495 TMTC1 -2,3257 
A_23_P3911 PLXDC1 -2,3037 
A_23_P127584 NNMT -2,2910 
A_23_P150162 DRD4 -2,2905 
A_23_P337262 APCDD1 -2,2844 
A_23_P90189 BBC3 -2,2805 
A_23_P143247 TSHZ2 -2,2713 
A_32_P108254 FAM20A -2,2708 
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